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ABSTRACT
MANGANESE SUPEROXIDE DISMUTASE CONTRIBUTES TO CISPLATIN-INDUCED
CYTOTOXICITY RATHER THAN ALL-TRANS RETINOIC ACID-DEPENDENT
CHEMORESISTANCE

Neuroblastoma is an extra-cranial solid tumor of the nervous system occurring
predominantly in infants and children younger than five years of age. Neuroblastoma
presents a challenge to therapy primarily due to a decreased responsiveness to anticancer agents like cisplatin (CDDP), leading to recurrence. Vitamin A and its
derivatives, known as retinoids, are preventive against cancer and induce differentiation
in some cell lines. Retinoids are now being tested clinically for the treatment of
neuroblastoma. One major limitation to retinoid therapy is the development of
chemoresistance. In the present study human SK-N-SH neuroblastoma cells pretreated
with 10 μM all-trans retinoic acid (ATRA) for 24 h followed by CDDP (0.5 - 25 μM),
exhibited a decrease in caspase-3 proteolysis and activity (24, 48, 72 and 96 h posttreatment).
In order to elucidate the mechanism of retinoid-mediated resistance we analyzed
levels of proteins regulated by nuclear factor kappa binding protein (NFκB) involved in
intrinsic apoptosis. Prior exposure to ATRA for 24 h enhanced bcl-xL and MnSOD levels
in the CDDP treated SK-N-SH cells which could contribute to chemoresistance.
Furthermore, ATRA pretreatment attenuated the CDDP-dependent increase in bax,
implicating a reduction in the proapoptotic protein to play a role in the observed drug
resistance. However, experiments using the SN50 inhibitor peptide suggested that
NFκB does not contribute to ATRA pretreatment-induced chemoresistance. This
conclusion further indicates that factors other than NFκB mediate the ATRA dependent
modulation of the intrinsic apoptotic process.
Continuing our investigation we observed that superoxide dismutase two (SOD2)
siRNA attenuated CDDP-dependent caspase-3 activity and cleavage, having no effect
on retinoid mediated chemoresistance under the conditions of the experiment. Similarly,
we found that the dominant negative against the retinoic acid receptor alpha (RARα)
produced no change in the retinoid-induced chemoresistance in the SK-N-SH cells. In
addition, we demonstrated that exposure to ATRA significantly increased
phosphorylation of the AKT protein at 30 min, 1h, 4 h, 24 h and 48 h time points. We
concluded that although MnSOD and RARα did not contribute to retinoid-induced
chemoresistance under the experimental conditions, activation of AKT may contribute,
at least in part, to the phenomenon.
The chemotherapeutic agent CDDP is frequently used to treat advanced stages
of many human cancers including neuroblastoma. The beneficial effect of CDDP in
treating malignancies is hypothesized to involve oxidative stress-induced apoptosis.
Oxidative stress also produces adaptive responses by altering the function and
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expression of several proteins including the superoxide dismutase (SOD) enzymes.
However, little is known about the role of the endogenous SOD enzymes in
neuroblastoma chemoresistance to CDDP. In the current study CDDP (5-25 µM)
significantly increased MnSOD activity and mRNA independent of concentration and
NFκB activity in SK-N-SH cells. In contrast, CDDP decreased Cu/ZnSOD expression
without altering the activity. Suppressing MnSOD gene expression using siRNA
technology resulted in a significant decrease in CDDP-dependent caspase-3 activation
and cleavage suggesting that MnSOD in part, potentiated apoptosis. The ability of
MnSOD to contribute to CDDP-induced apoptosis was hypothesized to result from the
prooxidant effects of hydrogen peroxide produced by the dismutation reaction. In
support of this hypothesis, prior incubation of the SK-N-SH cells with the thiol
antioxidant, N-acetyl-L-cysteine (NAC), reduced CDDP-mediated increases in caspase3 activity.
Following the preceding studies, we established an increase in MnSOD
expression and an acute ATRA pretreatment dependent chemoresistance in the SHSY-5Y cells consistent with that observed in the SK-N-SH neuroblastoma line. The
findings of the present report established for the first time that ATRA induces
chemoresistance within 24 h of prior exposure to the retinoid. This finding suggests that
caution should be taken while developing therapeutic strategies using ATRA as a
therapeutic tool in neuroblastoma. The present report also provides data elaborating on
the possible mechanism by which MnSOD contributes to CDDP-induced apoptosis in
neuroblastoma, thereby allowing the development of better therapeutic regimens to
treat the disease.
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CHAPTER I – INTRODUCTION

NEUROBLASTOMA

1.1 Description and epidemiology
The neuroblastic family of tumors consisting of ganglioneuroblastoma (intermixed
and nodular), ganglioneuroma and neuroblastoma, are derived from primordial neural
crest cells destined for the adrenal medulla and the sympathetic nervous system (Rha
et al., 2003). The most common extracranial solid tumor of childhood, neuroblastoma,
has an overall occurrence of 7-10% of the tumors in children less than 15 years of age
(Urayama et al., 2007; Papaioannou and McHugh, 2005; Berthold and Hero, 2000).
Neuroblastoma is the leading malignancy in infants (28% of cancer cases) with
approximately 60% of the tumors being diagnosed during the first 3 months of life. In
infants with disseminated disease, neuroblastoma generally has a favorable outcome
following surgery and chemotherapy. Unfortunately 70% of the cases of neuroblastoma
are diagnosed after metastasis has occurred resulting in a 5 year survival rate of less
than 40% and accounting for 15% of all pediatric oncology deaths (Maris et al., 2007).
The disease has a wide diversity in biological presentation and clinical behavior.
Although very rare, neuroblastoma is also observed to occur in adults (Meltzer, 1926).

1.2 Clinical presentation
1.2.1 Localized neuroblastoma
As neuroblastoma arises from neural crest cells destined for the sympathetic
nervous system, the tumors can occur in the adrenal glands, the organ of Zuckerkandl
or the sympathetic ganglia along paraspinal areas from the neck to the pelvis (Rha et
al., 2003). The presence of localized neuroblastoma is diagnosed in approximately 40%
of the cases as a palpable mass most frequently observed in the adrenal glands (35%)
and the paraspinal ganglia (30-35%) followed by the mediastinum (20%). Less common
sites are the pelvis (2%-3%) and neck (1%-5%) while some unusual locations of
neuroblastoma include the thymus, lung and kidney (Lonergan et al., 2003). The site of
localized neuroblastoma and its extent are reflected in the presenting signs and
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symptoms, although patients with tumor confined within a small area are often
asyptomatic (Weinstein et al., 2003). Some tumors are discovered on prenatal
ultrasonography, while others are detected incidentally on chest radiographs. The chief
paraneoplastic syndromes generally observed in the presence of localized malignancies
include opsoclonus-myoclonus syndrome (rapid eye movements, ataxia and irregular
muscle contractions) and profuse diarrhea in cases when the tumor secretes vasoactive
intestinal peptide (Hiorns and Owens 2001).
1.2.2 Metastatic neuroblastoma
Children with disseminated disease generally have extensive tumor burden that
has metastasized to cortical bone, liver and lymph nodes. They present to be severely ill
with symptoms ranging from abdominal distension, generalized skeletal pain to weight
loss, anemia, limping, fever and irritability (Weinstein et al., 2003). Metastasis to the
orbit results in periorbital ecchymoses (racoon eyes) present as dark circles around the
eyes (Lau et al., 2004). Additional findings include renin-associated hypertension, bowel
or bladder dysfunction, dyspnea, neurological deficits or cord compression signs
(Lonergan et al., 2002; Hiorns and Owens 2001).
1.2.3 Neuroblastoma classified as 4S disease
In about 5% of the cases of neuroblastoma a striking clinical phenotype of the
disease occurs with small localized primary tumors that metastasize to the liver, skin or
bone marrow and almost always spontaneously regress (D’Angio et al., 1971).
However, in certain cases (infants<2 months) rapid and extensive progression of the
malignancy may occur resulting in respiratory distress (Maris et al., 2007).

1.3 Risk factors and tumor pathobiology
The causative risk factors for neuroblastoma have not been identified
epidemiologically. The disease is not considered part of any developmental congenital
or inherited syndrome nor associated with any malignancy. However several genetic
aberrations have been identified in neuroblastoma, conforming the condition to the gene
2

theory of tumor development. Alterations in genes include both chromosome gains and
losses along with abnormalities in DNA index. Allelic gains on chromosome 17q are
found to be the most common genetic abnormality in neuroblastoma associated with an
increased risk of adverse outcome (Gilbert et al., 1984). Additionally the protooncogene
MYCN located in the distal end of the chromosome arm 2p has been reported to be
amplified to >10 copies in roughly 20% of the cases of neuroblastoma (Kushner, 2004)
again suggesting a high-risk case. In approximately 25-35% of the cases of
neuroblastoma a deletion of allelic 1p36 region is observed to occur, the importance of
which is debatable in unfavorable prognosis (Brodeur et al., 1981; Weinstein et al.,
2003). Moreover deletions on chromosome 11q and 14q are often observed in
neuroblastoma, the prior being strongly associated with an unfavorable outcome
(Attiyeh et al., 2005). Reports have demonstrated cellular DNA index to be a prognostic
marker especially in infants (Look et al., 1991). Neuroblastoma with a diploid DNA
content is considered to be resistant to chemotherapy whereas cases that are
hyperdiploid often being near triploid are correlated with early stage disease and
favorable prognosis (Bagatell et al., 2005).

1.4 Serum and molecular markers
Increased levels of certain molecules, although non-specific for neuroblastoma,
are considered to correlate with advanced stage neuroblastoma and poor survival rates.
High

serum

levels

of

neuron-specific

enolase

(NSE:

>100

ng/ml),

lactate

dehydrogenase (LDH: >1500 U/ml) and ferritin are associated with poor outcome in
neuroblastoma (Berthold et al., 1991; Woods, 1986; Silber et al., 1991). Neuroblastoma
is also diagnosed by the simultaneous detection of elevated catecholamine metabolites,
vanillylmandelic acid (VMA) and/or homovanillyl acid (HVA) in the urine or the serum
(Brodeur et al., 1993). The neurotrophin/tyrosine kinase receptors (TrkA, TrkB and
TrkC) and their ligands nerve growth factor (NGF), brain derived neurotrophic factor
(BDNF) and neurotrophin-3 are essential to neural cell survival, growth and
differentiation (Nakagawara, 2001). The TrkA and TrkC isoforms are highly expressed
in biologically favorable neuroblastoma cases with the A isoform being inversely related
3

to MYCN amplification status (Tanaka et al., 1995). Conversely, the TrkB receptor and
its ligand BDNF are commonly expressed in unfavorable tumors with MYCN
amplification being implicated for proliferation, chemoresistance and metastasis through
activation of the PI3 kinase pathway (Nakagawara et al., 1994).

1.5 Diagnosis
Neuroblastoma is diagnosed by either histopathologic evaluation of the
neoplastic tissue or by the observation of tumor cell clumps in the bone marrow aspirate
along with elevated levels of catecholamine metabolites. Additionally increased serum
concentrations of NSE, LDH, ferritin or chromogranin indicate high-risk conditions
although they are not independent prognostic factors, non-specific for neuroblastoma.
A variety of imaging techniques have been utilized to aid diagnosis and
evaluation of neuroblastoma and its progression to distant sites. Contrast-enhanced
computed tomography is the primary method for assessing tumors in the abdomen,
pelvis or mediastinum. Magnetic resonance imaging is preferred for distinguishing the
extent of tumor metastasis in the spinal canal (Ishola et al., 2007). Radiolabelled
metaiodobenzylguanidine (MIBG) scan is indicated to provide increased specificity and
sensitivity for detecting metastases to the bone (Andrich et al., 1996; Gordon et al.,
1990). The presence of neuroblastoma is confirmed by typical tumor cell clumps in bone
marrow aspirates or biopsy and the presence of cytogenetic abnormalities and tumor
biomarkers as analyzed in histologic sections. Cases with stroma-rich tumors, high level
of differentiation and low mitosis-karyorrhexis index (MKI: fewer than 100 mitotic cells
per 5000 cells) have a favorable prognosis. Other observations that suggest favorable
outcome include < 1 year of age, clinical stages 1, 2, 4S (Table 1) and MYCN
nonamplification.

1.6 Unique characteristics of neuroblastoma
A striking heterogeneity in histopathological features and response to therapy is
the clinical hallmark of neuroblastoma with a 5 year survival rate ranging from 25-95%.
4

Most high-risk neuroblastoma patients develop recurrent disease that is refractory to
further therapy (Kehalava et al., 2000). Neuroblastoma is uniquely found to have a high
rate of spontaneous regression with some metastatic neuroblastomas maturing into a
benign ganglioneuroma or progressing into disseminated disease (Jaffe, 1976;
Kushner, 2004).

These clinical observations encouraged in-vitro studies of

neuroblastoma differentiation (Reynolds and Lemons, 2001).

1.7 Staging
The international neuroblastoma staging system was framed in 1986 and subsequently
revised in 1993, which is now accepted worldwide (Table 1).
STAGE
Stage1
Stage 2A
Stage 2B
Stage 3

Stage 4
Stage 4S

DESCRIPTION
Localized tumor, complete gross excision; negative representative regional lymph
nodes
Localized tumor, incomplete gross excision; identifiable lymph nodes negative (ipsiand contralateral)
Localized tumor, complete or incomplete gross excision; ipsilateral positive regional
lymph nodes, contralateral negative lymph nodes
Unresectable tumor infiltrating across the midline, with or without regional lymph
node involvement OR midline tumor with bilateral extension by infiltration or by
lymph node involvement
Any primary tumor with dissemination to distal lymph nodes, cortical bone, bone
marrow, liver or other organs (except as defined in stage 4S)
Localized primary tumor, as defined for stage 1 or 2 with dissemination to liver, skin
or bone marrow. Only applies in infants <1 year of age.

Table 1. International Neuroblastoma Staging System (INSS) (Papaioannou and
McHugh, 2005)
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1.8 Histology
The presence of immature small, round shaped sympathetic cells known as
neuroblasts characterizes neuroblastoma. The Shimada system was first used to relate
histopathological features of neuroblastoma to clinical behavior (Shimada, 1984).
According to the Shimada classification neuroblastoma tumors were divided into
favorable and unfavorable groups based on a combination of patient age, MKI,
Schwannian stroma content and degree of neuroblast differentiation. Children <1.5
years of age with low or intermediate MKI and differentiating or partially differentiating
tumors were predicted to have a favorable outcome. Patients 1.5-5 years old with a low
MKI differentiating tumor were also included in the favorable outcome group. All other
combinations of age and MKI’s are suggested to have unfavorable outcome according
to the Shimada system (Lonergan et al., 2002).
The Pediatric Oncology Group (POG) classification (Table 2) is another system
used to classify neuroblastoma tumors into risk groups thereby providing the basis for
prognosis (Maris et al., 2007). According to the POG classification, patients with
neuroblastoma are divided into low-, intermediate- and high-risk categories. This system
takes into consideration age at diagnosis, INSS stage, histopathology, MYCN
amplification status and DNA index.

6

Stage

Age (days)

MYCN

Ploidy

Shimada
Histology

Other

1

Low

2A/2B

>50% resection

Low

<50% resection

Intermediate

Biopsy only

Intermediate

Amplified

High

<547
3

Intermediate

≥547

Favorable

Intermediate

Amplified

High

≥547

Unfavorable

High

<365
<365

4

Intermediate
Amplified

High

365-547

DI>1

365-547

DI=1

365-547

Favorable

Intermediate
High

Amplified

High

365-547

Unfavorable

High

≥547

4S

Risk Group

High

<365

DI>1

<365

DI=1

Favorable

Symptomatic

<365

Low
Intermediate

<365

<365

Asymptomatic

Unfavorable
Amplified

Intermediate
Intermediate
High

Table 2. Proposed children’s oncology group risk stratification schema by stage
(Maris et al., 2007)
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1.9 Neuroblastoma treatment
As a result of the unique hallmark characteristics of neuroblastoma the
propensity is to monitor the condition if diagnosed in stage 1 or 4S and administer
therapy only if necessary. Over the years, the strategy that evolved to treat the disease
is minimal therapy in low- and intermediate risk cases, while employing increased dose
intensity regimens for high-risk patients. Presence of localized tumor is generally
resolved by surgery. Residual tumors are observed and treated with combination
chemotherapy if necessary. In some cases, chemotherapy is used to reduce the tumor
to make it amenable to surgery. Disseminated tumors at diagnosis are treated with high
dose induction combination chemotherapy along with radiation and surgery tailored to
individual patients utilized to contain the malignancy (Berthold and Hero, 2000). The
INSS, Shimada and POG guidelines direct the treatment plan for neuroblastoma
according to the risk groups outlined in Table 2.
1.9.1 Low-risk neuroblastoma
Patients presenting with stage 1 and asymptomatic stage 4S neuroblastoma are
treated with surgery leading to a cure rate greater than 95% (Perez et al., 2000).
Residual microscopic tumors from stage 1 disease as well as disseminated lesions from
stage 4S are known to regress spontaneously. A favorable outcome is observed in
infants with stage 4S disease irrespective of the MYCN status (Nickerson et al., 2000;
Tonini et al., 1997) indicating that newborns with localized neuroblastoma require no
therapy and should be monitored only, to be treated in the unlikely case that
progression does occur. The patients with stages 2A and 2B also have survival rates
between 80 and 98% with the tumors being treated with surgery alone when necessary.
Chemotherapy is used for the low-risk stage 2 tumors if less than 50% of the tumor has
been resected or in the case of symptoms that cannot be relieved upon removal of the
mass. The common symptoms that lead to the use of chemotherapy include spinal cord
compression, respiratory distress, renal or bowel ischemia or gastrointestinal or
genitourinary obstruction. Chemotherapy given for 6 to 24 weeks consists of moderate
doses of carboplatin, cyclophosphamide, doxorubicin, and etoposide (Evans et al.,
1984). The cumulative dose of each agent is kept low to minimize permanent injury from
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the chemotherapy regimen. Certain neuroblastomas detected by screening in infants
may be followed without surgical intervention and pathologic diagnosis (Nishira et al,
2000; Holgersen et al., 1996). For patients presenting with the low-risk stage 4S type of
neuroblastoma therapy is required only due to complications such as painful bone
metastases and progressive hepatomegaly (Nickerson et al., 2000; Hsu et al., 1996).
1.9.2 Intermediate-risk neuroblastoma
A considerable variation exists in the outcome, and therefore, treatment of
patients with intermediate-risk stage 2 and 3 neuroblastoma with cure rates ranging
between 50 and 100% (Matthay et al., 1989; Matthay et al., 1998). In general, patients
older than one year of age are less likely to survive, even with intensive therapy,
resulting in cure rates as low as 40% (Castleberry et al., 1992; West et al., 1993).
Survival and treatment of patients classified as intermediate-risk with stage 4 INSS
disease is firmly associated with age, tumor cell ploidy and MYCN amplification (Paul et
al., 1991; Look et al., 1991; Schmidt et al., 2000). For intermediate-risk cases, patients
with favorable risk factors receive 12 weeks of chemotherapy whereas those classified
as unfavorable get 24 weeks (Shamberger et al., 1998). Radiation therapy is reserved
for patients with symptomatic life-threatening or organ-threatening tumors that do not
respond quickly to chemotherapy (Bowman et al., 1991).
1.9.3 High-risk neuroblastoma
Children older than 1 year, with widely disseminated tumors are classified as
high-risk cases that are challenging to treat due to a long-term survival rate between 10
and 40% (Mertens et al., 2001). The patients in this class receive an aggressive
regimen of combination chemotherapy that includes high doses of agents such as
cyclophosphamide, ifosfamide, cisplatin, carboplatin, vincristine, doxorubicin, and
etoposide (Matthay et al., 1999). Following exposure to multiple cytotoxic agents,
surgical resection of the tumor and stem cell rescue is demonstrated to be beneficial (La
Quaglia et al., 2004; Berthold et al., 2005). Radiation therapy is given based on
individual cases. In addition, oral 13-cis-retinoic acid for 6 months following
chemotherapy and radiation has been established to improve outcome (Haas-Kogan et
al., 2003; Matthay et al., 1999).
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CHAPTER II – LITERATURE REVIEW

2.1 Cisplatin (CDDP)
Cis-diammineplatinum (II) dichloride (cisplatin, CDDP) is one of the most
effective chemotherapeutic agents used to treat malignancies including ovarian,
testicular, bladder, cervical, and lung cancers (Rosenberg, 1999). Cisplatin is also
frequently used to treat advanced stages of neuroblastoma (Berthold and Hero 2000).
Unfortunately, despite its great effectiveness in treating several solid tumors, the
usefulness of CDDP has been limited by prominent side effects such as neurotoxicity
bone marrow suppression, ototoxicity, anaphylaxis and acute renal failure (Lebwohl and
Canetta, 1998; Ries and Klastersky, 1986). Moreover the curative potential of CDDP is
restricted by the presence or acquisition of resistance to the potent chemotherapeutic
agent (Ozols, 1992). Intercalation of DNA is established to be the primary mechanism of
CDDP toxicity with an increasing understanding of several facets of cellular alteration by
the chemotherapeutic agent (Roberts and Pera Jr, 1983; reviewed in Siddik, 2003).
However, a complete understanding of the mechanisms by which CDDP inhibits DNA
synthesis, suppresses RNA transcription, regulates cell cycle and initiates apoptosis is
necessary to improve efficacy and overcome resistance to the drug.
2.1.1 Mechanism of action of CDDP
Cisplatin is a neutral inorganic complex that becomes activated on entering the
cell by replacement of the chloride ions with water molecules (Kelland 2000). The
positively charged molecule then interacts with nucleophiles in the cell including protein,
RNA and preferentially DNA wherein it binds to the N7 sites of purine bases. This leads
to the formation of monoadducts, intrastrand and interstrand crosslinks between DNA
and activated CDDP (Eastman 1987). The intrastrand crosslinks account for 85-90% of
the total DNA lesions and are demonstrated to be the major cause of the observed
CDDP-dependent cytotoxicity (Kelland, 1993; Pinto and Lippard, 1985).
More than 20 individual proteins including those in the mismatch repair complex
(MMR) and the transcriptional factor, TATA binding protein (TBP) bind to the
intercalated DNA, leading to identification of the damage (Bellon et al., 1991; Fink et al.,
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1998; Chaney and Vaisman, 1999). A functional alteration in the proteins is known to
result from binding to the lesions, which relays the signal of DNA damage to
downstream effectors (Jordan and Carmo-Fonseca, 2000). Both pro-survival and proapoptotic effectors (signaling pathways) are activated in response to DNA damage from
CDDP exposure. The fate of the cell is then determined by the relative intensity,
duration and integration of the signaling molecules. Exposure to CDDP is found to
produce cell cycle arrest in the G2/M phase through inhibition of Cdc2-cyclin A or B
kinase in a variety of proliferating cells (Eastman, 1999). However cell cycle inhibition is
generally associated with nucleotide excision repair and cell survival depending on the
extent of DNA damage. The role of cell cycle checkpoint activation and arrest in CDDPinduced apoptosis therefore remains to be completely defined, but is chiefly connected
to activation of the tumor suppressor p53 (Bullock and Fersht, 2001).
The kinases ATM (Ataxia telangiectasia mutated protein) and ATR (ATM- and
Rad3 related protein) are known to regulate cell cycle progression and p53 stability.
Adducted DNA generated from exposure to CDDP preferentially activates ATR which
phosphorylates p53, thereby increasing its stability directly or through several other
proteins (Damia et al, 2001; Zhao and Piwnica-Worms, 2001, Appella and Anderson,
2001). The kinase CHK1 and proteins of the MAPK (mitogen activated protein kinase)
pathway are known to be stimulated by active ATR, leading to phosphorylation of p53 at
additional sites (Shieh et al., 2000; Persons et al., 2000). The protein p53 is a sequence
specific transcription factor demonstrated to be the chief mediator of the cytotoxicity
observed in response to the CDDP-induced DNA damage (Fan et al., 1994). The highmobility group 1 and 2 (HMG1 and 2) proteins have a great affinity for distorted DNA
resulting from exposure to CDDP (Thomas, 2001). These non histone proteins are
known to facilitate p53 binding to the DNA connecting nucleic acid damage to activation
of the proapoptotic transcription factor (Jayaraman et al., 1998).
Proteins involved in cell cycle arrest, DNA repair e.g. gadd45a, and negative
feedback regulation such as mdm2 are transcriptionally activated by p53 (Delmastro et
al., 1997; Alarcon-Vargas and Ronai, 2002). In addition CDDP-dependent increase in
p53 activates both intrinsic and extrinsic apoptotic processes by enhancing the
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transcription of proapoptotic bax and facilitating function of Fas/FasL respectively
(Hershberger et al, 2002; Muller et al., 1998).
Cisplatin exposure is demonstrated to induce apoptosis via the intrinsic pathway
in cervix carcinoma HeLa cells and head and neck carcinoma (Kamarajan et al, 2003;
Cullen et al, 2007). On the other hand, activation of the extrinsic death receptor pathway
mediates CDDP-induced apoptosis in LX-1 small cell lung carcinoma (Wu et al, 2005).
In addition, CDDP increases nuclear localization of apoptosis inducing factor in ovarian
cancer cells (Yang et al, 2008). Several reports including studies in human cell lines and
mice have suggested proteins of the mitogen activated protein kinase (MAPK) pathway
contribute to CDDP dependent cytotoxicity (Wang et al., 2000; Arany et al., 2004). The
members of the MAPK pathway are established to integrate extracellular signals
thereby regulating proliferation, differentiation, survival and apoptosis in cells (Dent and
Grant, 2001). Experiments by different groups have illustrated that ERKs (extracellular
signal regulated kinases), JNKs (c-Jun N-terminal kinases) and the p38 kinases are all
activated in response to CDDP (Wang et al., 2000; Arany et al., 2004). In addition,
activation of ERK was demonstrated to be critical for CDDP-initiated cytotoxicity in
human cervical carcinoma HeLa cells (Wang et al., 2000). Another suggested
mechanism by which CDDP induces apoptosis is through the generation of ROS
including hydroxyl free radical which compromises mitochondrial function (Baek et al.,
2003).
2.1.2 Mechanisms of resistance to CDDP
The primary aim of cancer chemotherapy is to destroy tumor cells through
apoptosis at the same time producing minimal damage to non-malignant tissue.
Although CDDP is a potent apoptosis inducer, one of the major limitations to its effective
use is the development of at least a two-fold resistance as observed in clinical studies
(Henkels and Turchi, 1997; Schilder and Ozols; 1992). However, studies in tumor cell
lines obtained from clinically unresponsive neoplasms have established the CDDP
resistance to be fifty to one hundred-fold higher compared to sensitive ones (Hagopian
et al., 1999). The mechanisms of resistance to CDDP encompass several possibilities
due to the complex nature of the action of the anticancer agent, from preventing entry of
12

the drug into the cell to alteration in the response of the apoptotic pathway, which is its
prime target. In general several mechanisms simultaneously contribute to the
development and presentation of resistance within the same tumor making it
challenging to therapeutically treat the malignancy (Teicher et al., 1987; Rabik and
Dolan, 2007).
A 20-70% reduction in the accumulation of CDDP has been reported in a variety
of cell lines displaying a three to forty-fold resistance to the chemotherapeutic agent
(Kelland 1993). In some cells a reduction in the accumulation of CDDP is the primary
mechanism of resistance whereas in other in-vitro models the level of the
chemotherapeutic agent does not correlate with decreased responsiveness (Kelland,
1993; Kelland et al., 1992). Inhibition of uptake, increase in the efflux or both may lead
to a reduction in accumulation of CDDP in cells. A reduction in uptake over a wide
range of CDDP concentrations has been demonstrated suggesting the possible
modulation of the passive drug diffusion process (Yoshida et al., 1994). An alteration in
Na+K+-ATPase dependent active transport may also play a minor role in the reduced
accumulation of CDDP in cells (Gately and Howell, 1993). The identification of exporter
proteins has brought attention to efflux as a potential mechanism of CDDP resistance.
One of the 7 members of the multidrug resistance protein (MRP) family, MRP2 is
observed to be higher in resistant bladder carcinoma cells (Kool et al., 1997). Moreover,
overexpression of MRP2 increases resistance while antisense to the transporter
enhances sensitivity to CDDP supporting its possible role in the process (Cui et al.,
1999; Koike et al., 1997). The copper transporting P-type ATPase genes ATP7A and
ATP7B are overexpressed in CDDP resistant tumor cells, the latter being proposed as a
clinical marker for decreased responsiveness to the chemotherapeutic agent in ovarian
cancer (Katano et al., 2002; Nakayama et al., 2002). In neuroblastoma cell lines,
increased malignant behavior with acquired multi-drug resistance was determined to be
unrelated to P-glycoprotein expression (Kotchetkov et al., 2005).
Cells contain abundant nucleophilic groups in the form of glutathione (GSH) and
cysteine rich metallothionein, which can neutralize active CDDP (Goto et al., 1999).
Both in-vitro and in-vivo studies have demonstrated an increase in GSH to be
associated with CDDP resistance (Wolf et al., 1987). The activation of c-jun by the
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enzyme gamma-glutamylcysteine synthetase (γ-GCS) is implicated to increase levels of
GSH (Pan et al., 2002). The elevated GSH can also increase DNA repair and attenuate
the drug-induced oxidative stress leading to resistance (Slater et al., 1995). The
overexpression of the antioxidant manganese superoxide dismutase (MnSOD) was
found to significantly attenuate CDDP dependent cytotoxicity in human embryonic
kidney cells suggesting that the enzyme may contribute to resistance to the anticancer
drug (Davis et al., 2001)
The activation of the PI3K/AKT pathway is associated with resistance to CDDP.
The AKT protein is observed to prevent nuclear accumulation of the CDK inhibitor p21
(Zhou et al., 2001). In addition, AKT phosphorylates Mdm2 and the protein bad, thus
inactivating the proapoptotic factor (Hayakawa et al., 2000). Phosphorylation of Mdm2
leads to the downregulation of the tumor suppressor p53 resulting in resistance (Oren et
al., 2002). Small molecule antagonists of Mdm2 are now proposed to be a novel therapy
in treating neuroblastoma (Van Maerken et al., 2006). Furthermore, loss in the function
of p53 due to mutation is observed in approximately 50% of all cancers resulting in
chemoresistance (Hollstein et al., 1991). Analysis of two neuroblastoma cell lines
derived from the same patient before [SKNBE (1n)] and after chemotherapy [SKNBE
(2c)] revealed a mutation in the p53 gene in the latter, may have contributed to
resistance (Tweddle et al., 2001).

2.2 Retinoids and cancer
Vitamin A is essential for fundamental life processes such as embryonic
development, vision, spermatogenesis, hematopoiesis, bone development and
differentiation (Summerbell and Maden, 1990). Deficiency of vitamin A has been
associated with the development of cancer as early as 1925 by Wolbach and Howe.
Ongoing studies provide evidence that addition of retinoids to a variety of human cancer
cell lines or tumor xenografts in nude mice leads to decreased growth, apoptosis and/or
differentiation (Simoni and Tolomeo, 2001). Retinoids are naturally occurring and
synthetic analogues of vitamin A such as all-trans retinoic acid (ATRA), which is the
primary metabolite, 13-cis retinoic acid and fenretinide. The primary source of retinoids
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is dietary, as animals are incapable of de novo synthesis of the vitamin. Carotenoids
from vegetables and retinyl esters from animals are converted to retinol in the intestinal
cells (Blomhoff et al., 1990). The retinol is then either stored as retinyl esters in the
stellate cells of the liver or carried by retinol binding protein (RBP) in the blood to the
extrahepatic tissues (Kanai et al, 1968; Wake, 1974). On delivery to the cells, retinol is
metabolized by dehydrogenases first to retinaldehyde and then to retinoic acid (Blaner
and Olson, 1994). A reduction in the ability to metabolize retinol was associated with the
increased observation of renal and breast carcinoma (Zhan et al., 2003; Hayder and
Satre, 2002). Moreover, a decrease in retinol and retinyl esters on exposure to
irradiation in hairless mice was implicated as the cause of the higher incidence of
melanoma (Sorg et al., 2002). Together, these reports along with others suggest that an
alteration in retinoid metabolism may lead to carcinogenesis.
The cellular retinol binding proteins (CRBP I and II) are known to facilitate uptake
of retinol into cells and direct intracellular metabolism or storage (Lane and Bailey,
2005). The CRBP I is ubiquitously expressed while the CRBP II is limited to the small
intestine associated with the generation of retinyl esters for chylomicron export (Ong et
al., 1994). On the other hand, cellular retinoic acid binding proteins (CRABP I and II)
present in the cytosol and nucleus are hypothesized to solubilize ATRA, functioning as
carriers to move the lipophillic retinoid to different subcellular compartments. Through
their interaction with ATRA, the CRAPB’s regulate ligand-retinoid receptor association,
thereby altering gene transcription (Delva et al., 1999; Zheng et al., 1996). In adults,
CRABP I is expressed ubiquitously whereas CRABP II is present in skin, uterus, ovary
and certain sections of the brain (Dong et al., 1999; Zetterstrom et al., 1999). Retinoic
acid regulates the levels of all binding proteins stimulating the expression of CRBP I and
CRABP II (Blaner et al., 1986; Kato et al., 1985). Studies conducted in squamous cell
carcinomas and human breast cancers have reported an alteration in the levels of
CRBP and CRABP, implicating a possible role for the proteins in transformation (Gates
and Rees, 1985; Kuppumbatti et al., 2001).

15

2.2.1 Retinoid receptors and signaling pathways
Retinoids primarily function by binding to specific nuclear retinoid receptors,
thereby changing conformation that promotes binding to the specific DNA sequences:
the retinoic acid response elements (RARE’s) leading to alteration of gene transcription
(Reynolds and Lemons, 2001). The retinoid receptors belong to the nuclear
steroid/thyroid hormone superfamily with which they share common structural and
functional properties (Giguere et al., 1987). The diversity of the retinoid-induced
signaling is mediated by receptors categorized into two subfamilies. The retinoic acid
receptors (RARα, β and γ) interact with high affinity to ATRA and 9-cis retinoic acid
(Heyman et al., 1992). The second subfamily consists of the retinoid X types of
receptors (RXR α, β and γ) which can be activated by 9-cis retinoic acid alone (Levin et
al., 1992). The receptor subtypes (RARα/β/γ and RXRα/β/γ) are each encoded by
different genes characterized by three major domains based on conserved sequence
and function (Chambon, 1996). The highly variable N-terminal domain activates
transcription whereas the conserved DNA-binding region contains two zinc fingers that
recognize specific nucleic acid sequences (Freedman, 1992). The C-terminal domain
regulates dimerization and transactivation in addition to interacting with the ligand
(Evans, 1988). The genes for the RAR subtype of the retinoid receptors are known to
generate RNA isoforms by alternate promoters or splicing, and by initiating translation at
an internal CUG codon (Zelent et al., 1991). In contrast, the gene for RXRγ alone is
found to produce isoforms in the RXR family (Liu and Linney, 1993).
The RAR’s function as heterodimers exclusively with RXR’s, in contrast, can form
heterodimers with several nuclear receptors for ligands such as ATRA, vitamin D3,
thyroid hormone, and peroxisomal proliferator activator (Yu et al., 1991; Keller et al.,
1993). The different isoforms of the retinoid family of receptors exhibit developmental
stage and tissue specific expression suggesting distinct function for each type, but
embryonic lethality results only when both alleles of the RXRα gene are disrupted
(Kastner et al., 1995). Studies in F9 teratocarcinoma cells with altered RAR genes have
suggested that the various retinoid receptors control specific pathways of RA-induced
differentiation (Faria et al., 1999). The activity of the retinoid class of receptors is
16

regulated by co-activators and co-repressors (Goodrich et al., 1993). In the absence of
the ligand the co-repressors bind to the receptor preventing transcription of target
genes. The co-activators, in contrast, interact with the receptors explicitly when the
ligand is bound to the receptor to enhance transcription (Chen and Evans 1995; Heery
et al., 1997)
A number of studies have reported changes in the expression or function of the
RAR’s and the RXR’s in different types of cancer. The production of a fusion protein
containing the RARα that prevents retinoid signaling was demonstrated to be the
primary cause of acute promyelocytic leukemia (Pandolfi, 2001). Promoter methylation
of the RARα2 isoform was observed in MCF-7 human breast carcinoma cells leading to
decreased expression of the receptor (Farias et al., 2002). A variety of tumor types
including squamous cell carcinoma, lung, stomach and neuroblastoma present with a
loss of RARβ expression (Xu et al., 1997; Qui et al., 1999). The RARγ isoform of the
retinoid receptor is reduced in the later stages of head and neck along with squamous
carcinoma cell lines (Klaassen et al., 2001). Although changes in the RXR’s can disrupt
several processes a reduction in expression was observed in thyroid cancer and
prostatic neoplasia alone (Haugen et al., 2004; Huang et al., 2002). Both families of
retinoid receptors are expressed in most neuroblastoma cell lines, primary tumors
expressing high levels of RARβ are associated with a favorable outcome in
neuroblastoma (Reynolds et al., 2003). However, RARβ4 has been demonstrated to
produce hyperplasia and neoplasia of several tissues in mice transgenic for the
particular isoform of the receptor (Xu, 2007).
The signaling pathways altered by activation of the retinoid family of receptors
are not completely elucidated. The activator protein-1 (AP-1), mitogen activated protein
kinase (MAPK) and phosphoinositide-3 kinase PI3K/AKT pathways are triggered by the
retinoids. However, it is likely that the retinoids exert tissue-specific influence on these
pathways (Niles, 2004). Although in most tissues retinoids down regulate AP-1, there is
an activation of the transcription factor in N1E-115 neuroblastoma cells during
differentiation induced by the vitamin A metabolites (deGroot and Kruijer, 1991).
Retinoids activate extracellular signal regulated kinase one/two (ERK 1/2), tissue
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transglutaminase and Rho A in SH-SY-5Y neuroblastoma cells which modulate the
neurite outgrowth and neuronal marker expression (Singh et al., 2003). In another study
c-jun N terminal kinase (JNK) was demonstrated to be essential to retinoic acid-induced
neurite outgrowth of SH-SY-5Y cells (Yu et al., 2003). Lopez-Carballo et al., 2002, also
reported that the retinoid-dependent activation of the PI3K/AKT pathway mediated
differentiation of the SH-SY-5Y neuroblastoma cells. Cell cycle inhibition by the retinoids
in neuroblastoma was demonstrated to be achieved by reduction in cyclin D and
stimulation of p27 expression blocking progression through the G1 phase (Matsuo and
Thiele, 1998). Although retinoids generate their effects primarily through nuclear RAR’s,
they may also act through receptor-independent mechanisms (Dmitrovski, 1997).
2.2.2 Retinoids and neuroblastoma differentiation
Non-proliferating,

differentiated

cells

arise

from

leukemias,

carcinomas,

melanomas and neuroblastoma either spontaneously or after induction by various
agents both in-vitro and in-vivo (Reiss et al., 1986). Neuroblastoma has the highest rate
of clinical spontaneous maturation or differentiation which leads to regression of tumors
(Everson 1964). The ability of retinoids to induce differentiation has been exploited
successfully to treat acute promyelocytic leukemia (APL) (Brietman et al., 1981).
Moreover, the efficacy of retinoids in cancer is attributed to the capacity to inhibit
proliferation, induce apoptosis or differentiation, or a combination of these actions (Hong
and Itri, 2000). These reports provide the basis for further studies to investigate the
usefulness of retinoids to antagonize neuroblastoma. Retinoid-induced differentiation is
characterized by alteration in morphology, biochemical activity and gene expression
(Reynolds and Lemons, 2001). The decrease in proliferation, neurite outgrowth,
synapse formation, induction of neuron specific proteins in neuroblastoma cells exposed
to retinoids correspond to changes in maturing neural crest cells (Sidell et al., 1983;
Tsokos et al., 1987). In addition, a flat epithelium-like phenotype correlated with cell
senescence has been consistently described in neuroblastoma lines treated with
retinoids (Wainwright et al., 2001).
The major vitamin A metabolite-ATRA is one of the most potent differentiation
inducers for human neuroblastoma in vitro (Sidell et al., 1983). Therapy of both MYCN
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gene-amplified and non-amplified human neuroblastoma cell lines with ATRA caused a
marked decrease in the RNA expression of the oncogene and arrested cell proliferation
(Thiele et al., 1985). The effect persisted in some cells more than 60 days after drug
removal. Re-exposure to ATRA prevented proliferation of cells that continued to multiply
suggesting that retinoid pulse therapy may cause sustained arrest of tumor cell
proliferation in some cases of neuroblastoma (Reynolds et al., 1991). In-vitro studies
have demonstrated induction of chemoresistance with ATRA that has limited use of the
potent differentiating agent (Lasorella et al., 1995). In order to increase the efficacy of
ATRA differentiation therapy, an understanding of the retinoid-induced changes in
various signaling pathways altering the process is essential.
2.2.3 Retinoids and chemoresistance in neuroblastoma
The use of ATRA as a differentiating agent in neuroblastoma is restricted by
several reports of chemoresistance induced by the retinoid (Lombet et al., 2001;
Lasorella et al., 1995). The bcl-2 and bcl-xL proteins are known to inhibit apoptosis by
antagonizing bax and bak that induce cell death through mitochondrial cytochrome c
release (Korsmeyer, 1995; Adams and Cory, 1998; Zha et al., 1996). This bcl-2 family
of proteins controls neuronal survival through modulation of apoptosis (Davies, 1995)
and have been explored for their involvement in ATRA induced chemoresistance. The
SK-N-SH neuroblastoma cells express bcl-2 and bcl-xL, the levels of which can be
modulated using differentiating treatments like ATRA (Reed et al., 1991; Dole et al.,
1991; Lasorella et al., 1995). In a study by Lasorella et al. (1995), six days of 5 μM
ATRA-induced differentiation significantly attenuated the cytotoxic effects of 10-40 μM
cisplatin in SH-SY-5Y cells. A consistent increase in the levels of bcl-2 in response to
the six day regimen of ATRA treatment in the SK-SH-N, SK-SH-F, SMS-KCNR and SHSY-5Y neuroblastoma cell lines led the authors to conclude that modulation of the antiapoptotic protein was responsible for the observed resistance. Similar results were
observed with six days of 20 μM ATRA treatment, which resulted in reduced
vulnerability to chemotherapeutic agents, including 5-100 μM cisplatin in the SH-SY-5Y
cell line (Tieu et al., 1999). On the contrary, analysis of chemosensitivity using 10 μM
ATRA versus 16 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) differentiation of the
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SH-SY-5Y cells for five days indicated that bcl-2 is not critical for resistance (Ronca et
al., 1999). In this study, ATRA selectively impaired chemotherapeutic apoptosis
mediated by p53. The authors then demonstrated that a reduction in the nuclear import
of the transcription factor p53 was responsible for the resistance. In another study in
SK-N-SH cells, Lombet and co-workers (2001) observed that 7 days of 3 μM ATRA
treatment increased bcl-xL, reduced bcl-2 and had no effect on the levels of bax
proteins. In addition, the ATRA pretreatment caused a decrease in 10 nM thapsigargin
induced cell death, which was attributed to the increased levels of anti-apoptotic bcl-xL.
There are therefore uncertainties regarding whether bcl-2 mediates ATRAinduced chemoresistance in the SH-SY-5Y cells and needs to be explored further along
with the involvement of p53 in the process. In comparison bcl-xL is responsible for ATRA
induced chemoresistance in the SK-N-SH cells. The latter is supported by the
observation that overexpressing bcl-xL prevents cisplatin-induced cell death in
neuroblastoma cells along with studies demonstrating that an inhibitor of bcl-xL
potentiates the effects of cytotoxic drugs (Shoemaker et al., 2006). Recent studies have
suggested that differentiating agents may be activating pathways such as NFκB, to
upregulate bcl-xL and promote cell survival (Kucharczak et al., 2003). Future studies
should identify upstream mediators of the NFκB pathway which contribute to
chemoresistance thereby providing pharmacological targets to improve clinical use of
retinoids.
Recent studies have reported ATRA-dependent rapid nongenomic activation of
the PI3 kinase pathway in the SH-SY-5Y human neuroblastoma cells mediated by the
retinoic acid receptor (Masia et al., 2007). At the same time investigation of 116 primary
neuroblastoma samples revealed increased phosphorylation of AKT as a novel
prognostic indicator of decreased event-free or overall survival in neuroblastoma (Opel
et al., 2007). The activated AKT status correlated with variables of aggressive disease
such as MYCN amplification, advanced stage of tumors and unfavorable histology.
These reports suggest a possible role of the AKT pathway in ATRA-induced
chemoresistance providing the basis for further investigation.
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2.3 Cellular redox regulation
All aerobic life forms use molecular oxygen to generate energy in the form of
ATP (Gloire et al., 2006).

Highly reactive intermediates known as reactive oxygen

species (ROS) are produced primarily as a byproduct of cellular respiration. Superoxide,
hydrogen peroxide and hydroxyl free radical are the major ROS generated which can
also result from the activity of enzymes such as the NADPH oxidases, lipoxygenases
and cycloxygenases (van Heerebeek et al., 2002; Kuhn and Thiele, 1999; Kuehl and
Egan, 1980; Fridovich, 1978). Being highly reactive, the ROS interact with lipids,
proteins and DNA/RNA, thus modulating activity of a variety of signaling pathways, and
altering cellular processes such as the immune response, cell cycle and apoptosis
(Thannical and Fanburg, 2000; Kabe et al., 2005; Poli et al., 2004; Shackelford et al.,
2000; Simon et al., 2000). Further studies have demonstrated hydrogen peroxide to be
the primary ROS mediating cellular signaling because of its capacity to inhibit tyrosine
phosphatases (Tonks, 2005).
Under normal physiological conditions, ROS are rapidly eliminated by the celluar
antioxidant system of enzymes constituting the superoxide dismutases (SOD 1, 2 and
3), catalase, glutathione peroxidase (GPx) and peroxiredoxin (PRx) (Thannical and
Fanburg, 2000) preventing potential damage. A state of oxidative stress results when
the cellular production of ROS supersedes the capacity of the antioxidant enzymes.
Subsequent cellular damage, including apoptotic cell death, is established to contribute
to the pathogenesis of several diseases. In addition, depletion of the antioxidant
enzymes by the overproduced ROS is responsible for further oxidative damage, as the
cells are unable to eliminate the free radicals (Lewen et al., 2000). Cardiovascular
diseases, diabetes, neurological abnormalities and cancer are some of the conditions
associated with aberrant ROS production (Ferrari et al., 2004; Valko et al., 2007)
2.3.1 Superoxide dismutases
Under basal conditions, about 1-2% of the oxygen processed by the
mitochondria is converted to superoxide (Lewen et al., 2000). The three SOD enzymes
are the primary endogenous antioxidants that dismutate the superoxide free radical into
hydrogen peroxide which is then eliminated by catalase and GPx (Oberley, 2005). The
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manganese containing SOD (MnSOD) is present in the mitochondrial matrix being
available to quench superoxide at its chief source, providing an excellent mechanism to
prevent cellular oxidative stress (Weisiger and Fridovich, 1973). Extracellular SOD
(ECSOD) is found outside the plasma membrane, while the copper- and zinc-containing
SOD (Cu/ZnSOD) exists mainly in the nucleus and cytoplasm with low levels present in
the mitochondrial intermembrane space (Okada-Matsumoto and Fridovich, 2001).
The human MnSOD gene (SOD2) is located in chromosome 6q25 of the nuclear
DNA as a single copy composed of 5 exons and 4 introns (St. Clair et al., 2002). The
SOD2 is evolutionarily conserved sharing more than 90% homology in sequence in a
variety of organisms including algae, yeast, humans and rats (Misra and Fridovich,
1977; Dhar et al., 2006). The MnSOD protein is synthesized with a 24 amino acid leader
peptide. The pro-enzyme is then proteolytically processed into a 24 kDa protein being
imported in an energy dependent manner into the mitochondria (Wispé et al., 1989).
The enzyme MnSOD is a homotetrameric protein that contains one manganese ion per
subunit and is reported to be essential for survival due to the ability to eliminate
superoxide (Weisiger and Fridovich, 1973). Lethality within 10 days due to dilated
cardiomyopathy, metabolic acidosis and increased lipid levels in the liver and skeletal
muscle was observed in mice that were homozygous for a mutant form of MnSOD (Li et
al., 1995). The heterozygous MnSOD gene knockout mice had a significant increase in
cancer rates although they were as susceptible to oxygen toxicity as their wild type
littermates (Tsan et al., 1998; van Remmen et al., 2003).
2.3.2 Regulation of MnSOD expression
The MnSOD gene is responsive to a variety of endogenous and exogenous
stimuli. Hyperoxia, irradiation, certain chemicals and activated inflammatory cells
increase the production of ROS (Warner et al., 1996). Both in-vivo and in-vitro
experiments have demonstrated that MnSOD is critical for protection against oxidant
injury (Wan et al., 1993; Wispé et al., 1992). The enzyme MnSOD is ideally suited to
provide a buffer against oxidative stress induced injury as expression of the protein is
regulated by an alteration in the cellular redox status. A 50% increase in MnSOD activity
was first reported by Crapo and Tierney, 1974, in the lungs of rats exposed to 85%
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oxygen for 7 days. Higher levels of MnSOD possibly contributed to hyperoxia tolerance
(Crapo and Tierney, 1974). Pretreatment of pulmonary adenocarcinoma cells with Nacetyl-L-cysteine (NAC) attenuated the tumor necrosis factor alpha (TNFα) dependent
increase in MnSOD, suggesting that ROS contribute to the induction of the antioxidant
(Warner, 1996). Subsequently, other oxidants such as thiol modulating agents were
shown to increase MnSOD activity in lung adenocarcinoma and fibroblast cells (Das et.
al., 1995; Wan et al., 1993).
The proapoptotic p53 protein differentially regulates MnSOD expression. Several
p53 binding consensus sequences have been identified in the MnSOD promoter. This
finding was verified by the observation that induction of p53 enhanced MnSOD
expression in human fibroblasts. Higher level of MnSOD was demonstrated to mediate
p53-dependent apoptosis (Hussain et al., 2004). In contrast to the previous report,
transfection of wild type p53 in HeLa cells significantly reduced both MnSOD mRNA
levels and enzyme activity suggesting the proapoptotic factor negatively regulates
expression of the protein (Pani et al., 2000). An interaction with specificity protein 1
(Sp1) was contributed to the p53-induced decrease in MnSOD expression (Dhar et al.,
2006). A number of overlapping binding sites for the transcription factors Sp1 and
activator protein 2 (AP-2) have been identified in the promoter of the human MnSOD
gene (Xu et al., 2000). The protein Sp1 was found to be essential and sufficient for
MnSOD expression, whereas AP-2 antagonized expression. Experiments with the
individual isoforms of AP-2 have demonstrated that AP-2α and AP-2γ were stronger
repressors of MnSOD expression than AP-2β (Zhu et al., 2001).
An NFκB response element was identified in an enhancer in the 2nd intron of the
MnSOD gene. Mutation of the intronic site abolished activation of the gene by cytokines
suggesting it is an integral part of phorbol 12-myristate 13-acetate (PMA), TNFα and
interleukin-one beta (IL-1β) dependent MnSOD expression (Kiningham et al., 2001).
This report was supported by later experiments showing that inhibitory kappa B alpha
(IκBα) is a labile repressor of MnSOD expression (Kiningham et al., 2004). In
endometrial stromal cells, the redox sensitive transcription factor NFκB is essential for
TNFα and protein kinase C (PKC)-induced MnSOD expression (Sugino et al., 2002).
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Furthermore, activation of NFκB alleviated radiation-induced damage in prostate cancer
cells by inducing MnSOD expression (Josson et al., 2005). In addition, phorbol ester
dependent MnSOD expression was mediated by PKC through cyclic AMP response
element binding protein one CREB-1/ATF-1 like factor and Sp1 (Kim et al., 1999;
Tanaka et al., 2000)
Anticancer drugs such as vincristine and vinblastine increase MnSOD expression
(Das et al., 1998). The chemotherapeutic agent paclitaxel also enhanced MnSOD
expression in the human lung adenocarcinoma cell line A549, in a concentration and
time dependent manner through increased PKC-δ activity. In addition to the
chemotherapeutic agents, reducing agents such as NAC, dithiothreitol (DTT) and 2mercaptoethanol regulate MnSOD expression. Exposure of A549 lung adenocarcinoma
cells to the reducing agents increased MnSOD mRNA and enzyme activity through
NFκB (Das et al., 1995). Moreover, we recently reported the differentiating agent ATRA
significantly increased MnSOD expression in the SK-N-SH neuroblastoma cells
(Kiningham et al., 2008)
Certain cytokines and hormones regulate MnSOD expression. Tumor necrosis
factor-α (TNFα) enhanced MnSOD mRNA in human endometrial and pulmonary
adenocarcinoma cells in a concentration and time dependent manner (Sugino et al.,
2002; Warner et al., 1991). Lipopolysaccharide (LPS) and IL-1 are other inflammatory
molecules which also regulate expression of MnSOD (White and Tsan, 2001; Suzuki et
al., 1993). Nerve growth factor (NGF) increases MnSOD expression through early
oxidative signals that activate the phosphatidylinositol 3-kinase (PI3K) pathway and the
cAMP-responsive element binding protein (CREB) (Bedogni et al., 2003). Exposure of
the human breast cancer cell line MCF-7 to estradiol rapidly increased MnSOD activity
and inhibited ultraviolet radiation-induced cell death (Pedram et al., 2006).
2.3.3 MnSOD and Cancer
Absence of MnSOD activity and therefore hydrogen peroxide in neoplastic
tissues in comparison with normal tissue was first reported in isolated hepatoma
mitochondria (Dionisi et al., 1975). Cullen et al., 2003, then showed that although
Ehrlich ascites tumor mitochondria contained some SOD activity, they did not generate
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hydrogen peroxide. An inverse relationship was found between MnSOD expression and
pancreatic cancer cell proliferation with overexpression of the antioxidant decreasing
growth (Cullen et al., 2003). The expression of MnSOD was correlated with
chemosensitivity in human gastric cancer cell lines (Hur et al., 2003). Studies in human
breast cancer cell lines MCF-10A, MDA-MB231 and MCF-7 showed that increasing
MnSOD activity using adenovirus inhibited cell growth, clonogenic survival and
xenograft proliferation as compared to controls (Weydert et al., 2006). Hu et al.
demonstrated MnSOD to be a tumor suppressor in ovarian cancer by showing that
decreasing the enzyme led to a corresponding increase in cell proliferation (2005).
Enhancing MnSOD expression in the UAcc-903 melanoma cell line altered cellular
morphology and decreased colony formation in soft agar as compared to controls
(Church et al., 1993).
An increase in hydrogen peroxide is implicated as the chief mediator of MnSODdependent tumor suppression. Studies in colorectal cancer have reported that the
generation of hydrogen peroxide by MnSOD activates caspase-8 leading to decreased
expression of the anti-apoptotic protein bcl-2, which subsequently increases apoptosis
(Zhang et al., 2006). Studies by Li et al., in human prostate carcinoma cells showed that
MnSOD overexpression lead to mitochondrial damage and altered membrane potential
through increased production of hydrogen peroxide (1998). The intracellular redox
status plays an important role in the tumor suppressor effect of MnSOD as
overexpression of GPx attenuated growth inhibition of human glioma cells induced by
the superoxide dismutating enzyme (Li et al., 2000). Furthermore, studies in a
multistage skin carcinogenesis model demonstrated that PKC dependent inhibition of
AP-1 contributed to the decreased papilloma formation in MnSOD overexpressing
transgenice mice as compared to their non-transgenic counterparts (Zhao et al., 2001).
In comparison to the previous studies high levels of MnSOD have been
associated with aggressive tumor characteristics. A significantly higher total SOD
activity was observed in lung cancer as compared to the nontumor tissue (Ho et al.,
2001). The expression of MnSOD and enzyme activity was higher in radiation resistant
versus sensitive prostate carcinoma cell lines higher levels of NFκB conferring the
survival advantage (Josson et al., 2006). Increased expression of MnSOD in gastric
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carcinoma was associated with poor survival (Janssen et al., 2000). This finding was
supported by the observation of increased MnSOD expression in metastatic versus
nonmetastatic gastric tumors (Malafa et al., 2000).
Squamous carcinoma cells transfected with MnSOD antisense and inoculated
into nu/nu mice were more sensitive to apoptosis induced by γ-rays and anticancer
drugs, including CDDP and 5-fluorouracil compared to those cells receiving control
vectors (Ueta et al., 2001). An increase in the expression of the proapoptotic bax, bak
and p21 along with a suppression of bcl-2, bcl-xL and cyclooxygenase-2 were implicated
in the higher sensitivity of squamous carcinoma cells transfected with MnSOD
antisense. Hirose et al., 1993, reported that transfection of MnSOD sense cDNA in the
A375 human melanoma cell line prevented TNFα and IL-1α-dependent cytotoxicity.
An increased expression of MnSOD in response to ROS-generating drug therapy
and radiation has been associated with increased resistance to apoptosis in diverse
tissue types. Induction of MnSOD mediates the cardioprotective effect of tamoxifen by
both in-vivo and in-vitro experiements (Daosukho et al., 2005). Etoposide-dependent
increase in MnSOD without an alteration in bcl-2 proteins was suggested to be
responsible for the lower sensitivity of the acute myeloblastic leukemia cells to the
anticancer agent (Mantymaa et al., 2000). Studies in human breast cancer cells showed
that overexpression of MnSOD conferred resistance to TNFα and/or hyperthermiainduced toxicity (Li and Oberley, 1997). Quick et al., 2008, demonstrated that chronic
treatment of mice with SOD mimetics significantly extended lifespan by reducing ageassociated oxidative stress and mitochondrial free radical production.
2.3.4 MnSOD in neuroblastoma
Human

neuroblastoma

IMR-32

cells

were

analyzed

before

and

after

differentiation with dibutyryl cAMP (1mM) or 5 bromo-deoxyuridine (4 µM) for redox
status changes, which play an important role in the cytotoxicity induced by anticancer
agents (Erlejman and Oteiza, 2002). An increase in the activity of both SOD enzymes
was reported in the IMR-32 cells after differentiation along with reduced catalase activity
and expression. The report suggested that differentiated neuronal cells may be highly
susceptible to oxidant mediated damage as a result of the alteration in activity of the
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different

antioxidant

enzymes.

Analysis

of

serum

samples

of

patients

with

neuroblastoma revealed MnSOD levels were significantly higher suggesting the
antioxidant protein to be a potential prognostic marker of the disease and its response
to chemotherapy (Kawamura et al., 1992). Studies in tumors of neuroepithelial origin
have shown that MnSOD is associated with a loss of differentiation, increase clinical
malignancy and poor prognosis (Landriscina et al., 1996). In addition, analysis of grade
IV astrocytomas and medulloblastomas led to the observation that the tumors have
higher levels of MnSOD as compared to normal brain specimens (Cobbs et al., 1996).
Differentiation treatment of SH-SY-5Y and SMS-KCNR neuroblastoma cells (10
µM ATRA, six days) reduced apoptosis in response to CDDP and adriamycin (Lasorella
et al., 1995). The present study was designed to determine whether an acute exposure
of 24 h could result in a similar resistance. Experiments were also planned to delineate
the mechanism of the ATRA-induced resistance to neuroblastoma. Although MnSOD
reduced CDDP-induced apoptosis in in-vitro and in-vivo models, contribution of the
enzyme to chemoresistance in neuroblastoma has not been defined. In a recent report,
studies from our laboratory have demonstrated that ATRA increased MnSOD
expression in the SK-N-SH cells through activation of the NFκB pathway. This led us to
the hypothesis that NFκB-dependent modulation of apoptosis through its target genes
involved in the intrinsic pathway and the antioxidant MnSOD contributed to
chemoresistance in the presence of ATRA in neuroblastoma (Fig. 2.1). Moreover, in
view of the retinoid receptors playing a primary role in ATRA effects we proposed the
nuclear proteins to contribute to the observed chemoresistance. Finally activation of the
PI3K/AKT pathway is associated with unfavorable outcome in neuroblastoma. In
addition ATRA-dependent activation of the PI3K/AKT is a requisite for differentiation
induced by the retinoid prompting us to hypothesize that the prosurvival pathway may
play a role in the observed chemoresistance.
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HYPOTHESIS

Figure 2.1 Hypothesized mechanism of ATRA-induced chemoresistance.
Prior exposure to ATRA is hypothesized to activate NFκB through an increase in the
level of ROS which alter the redox status of the cell. The activated transcription factor
NFκB can then modulate the expression of target genes including bcl-xL and bax
involved in intrinsic apoptosis thereby causing resistance to CDDP. The antioxidant
MnSOD was also hypothesized to contribute to the ATRA-induced chemoresistance as
the enzyme is upregulated in response to ATRA through NFκB in the SK-N-SH cells
(Grey arrows – ATRA pretreatment induced effects; Black arrows – CDDP-induced
effects).
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AIMS OF THE STUDY

Based on the hypothesis in the present study we utilized the human SK-N-SH
and SH-SY-5Y cell lines to investigate the cellular alterations induced by the potent
differentiating agent ATRA in neuroblastoma. The experiments were designed to
determine whether:


Acute (24 h) pretreatment with ATRA induces resistance to CDDP



The transcription factor NFκB and its target genes including MnSOD are
involved in ATRA-induced chemoresistance



The RAR’s contribute to ATRA-dependent chemoresistance



Exposure to ATRA alters the prosurvival PI3K/AKT pathway
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CHAPTER III – MATERIALS AND METHODS

3.1 Cell culture
The SK-N-SH neuroblastoma cell line was purchased from American Type
Culture Collection and cultured in minimal essential medium supplemented with 10%
heat-inactivated fetal bovine serum, 1% penicillin, streptomycin, and neomycin
antibiotics (Invitrogen Corp., Carlsbad, CA), 1% nonessential amino acids, and 1 mM
sodium pyruvate. SK-N-SH cells were incubated at 37°C in a humidified atmosphere of
5% CO2. Previous studies in the laboratory have established minimal change in
doubling time between passages 40 and 68 of the SK-N-SH cells. Also, there was no
difference in the expression of the cellular markers microtubule-associated protein 2
(MAP2; specific for neurons) and synaptophysin (SYP; integral membrane protein
involved in the formation of synaptic vesicles) between passages 41 and 53 of the SKN-SH cells as examined by western analysis. In view of these results all experiments
were conducted between passages 41 and 60 of the SK-N-SH cells.

3.2 Chemicals
All chemicals including dimethylsulfoxide (DMSO), all-trans retinoic acid
(minimum 98% HPLC), cis-diamminedichloroplatinum (II) (99.9%), N-acetyl-L-cysteine,
Ponceau S, sodium pyruvate, 3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) and ethidium bromide were purchased from Sigma-Aldrich Chemical
Corporation (St. Louis, MO) unless otherwise stated.

3.3 Treatment of cells with CDDP and ATRA
A review of published literature indicated a broad range of CDDP concentrations
(1-100 μM) could be employed to induce apoptosis, depending on the sensitivity of the
cell line under consideration (Guruswamy and Benbrook, 2006; Qian et al., 2005;
Mabuchi et al., 2004). For the present set of studies, we assessed sensitivity using the
MTT assay, for which we exposed the SK-N-SH line to a limited range of CDDP
concentrations (0-25 μM) that decreased survival by approximately 40% within 24 h in
the cells. Cisplatin is readily soluble in the medium employed to maintain the SK-N-SH
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cells in culture whereas DMSO was used as a vehicle for ATRA. In preliminary
experiments, we observed that 10 μM ATRA attenuated proliferation, produced
differentiation and chemoresistance in the SK-N-SH neuroblastoma cells without
inducing apoptosis. All of the subsequent experiments were therefore conducted using
10

μM

ATRA.

In

order

to

evaluate

ATRA

(10

μM)

pretreatment-induced

chemoresistance, we treated the cells with either DMSO (0.05%) or the retinoid for 24 h.
Exposure to the vitamin A metabolite was followed by vehicle, ATRA (10 μM), CDDP
(0.5-10 μM) or the latter two together for 24, 48, 72 or 96 h as indicated. The protocol
therefore constituted a 24 h pretreatment of the cells with 10 μM ATRA prior to CDDP
(0.5-10 μM) and continued retinoid exposure. The experiments were conducted under
yellow light, and the treated SK-N-SH cells were stored in the dark as ATRA is light
sensitive. Media containing the treatments were replaced every 48 h for experiments
continuing until 96 h. All of the experiments were repeated at least three times. In Fig.
4.20, the SK-N-SH cells were incubated with or without the thiol antioxidant NAC (1
mM) for 24 h. This incubation was followed by exposure to either NAC (1 mM) or CDDP
(10 μM) for the next 24 h at the end of which the cells were harvested and analyzed for
caspase-3 activity.

3.4 Treatment of cells with SN50 inhibitor peptide
The SK-N-SH cells were plated (1.5 x 106/p100 plate) and treated with vehicle
(0.05% DMSO), ATRA (10 µM), NFκB SN50 cell-permeable inhibitor peptide (10 µg/ml;
Calbiochem, Gibbstown, NJ) or a combination of the latter two for 48 h. Whole cell
lysates obtained for the different

treatments were analyzed for the expression of

MnSOD and N-methyl-D-aspartate one (NMDAR1).
In order to determine the contribution of the transcription factor NFκB in
chemoresistance, SK-N-SH cells were plated (2 x 103/well; 96 well plates) and
incubated in the presence or absence of SN50 (10 µg/ml) in addition to the treatments
mentioned previously. Retinoid-induced reduction of CDDP-dependent toxicity was then
evaluated using CellTiter-Glo (Luminescent cell viability assay, Promega, Madison, WI).
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3.5 MTT assay
In order to determine viability, the SK-N-SH cells were seeded in a 96-well flatbottom plate (4 X 104 cells/well in 100 μl of medium). On the next day, the cells were
exposed to a range of CDDP concentrations (0-25 μM) for 24 h. The treatments were
carried out in replicates of five wells each with medium as the blank. The MTT reagent
was prepared by dissolving 5 mg/ml in phosphate buffered saline (PBS; pH 7.4)
followed by sterile filtration. Four hours before the end of the 24 h incubation with
CDDP (0-25 μM), 10 μl of MTT was added to each well. After incubation with MTT at
37°C for 4 h, the media was aspirated and replaced with 50 μl of 100% DMSO in each
well, dissolving the formazan salt crystals by repeated pipetting. The MTT assay was
carried out under yellow light to minimize degradation of the reagent used. Absorbance
was measured on a plate reader (Molecular Devices Corp., Sunnyvale, CA) at a
wavelength of 570 nm (Mosmann, 1983) and the results were reported as percentage of
control.

3.6 Isolation of cytoplasmic extracts and whole cell lysates
Treated SK-N-SH cells were scraped in the medium and washed twice in cold
phosphate buffered saline (PBS; pH 7.4) followed by centrifugation (1500 rpm, 10 min,
4°C) to obtain the pellet. In order to acquire cytoplasmic fractions, cells were
resuspended in lysis buffer [10 mM HEPES-KOH, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol (DTT), 5 mM NaF, 1 mM NaVO3, Complete Mini (15%; Roche,
Indianapolis, IN), H2O] and incubated on ice for 15 min. After incubation, 10% of the
detergent NP-40 was added, and the suspension vortexed for 15 sec followed by
centrifugation (14,000 rpm,1 min, 4°C). The supernatant, containing the cytoplasmic
fraction, was collected and frozen at –80°C until analyzed. For whole cells lysates, the
pellets, obtained after the PBS washes were resuspended in 0.05M phosphate buffer
(pH 7.8), vortexed, and frozen (–80°C) prior to analysis.

3.7 Protein analysis
The protein content of cytoplasmic extracts and whole cell lysates was quantified
using the BioRad assay with bovine serum albumin (BSA) as the standard. A working
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solution (50 μg/ml) was prepared using a 50 mg/ml stock to obtain the BSA standards
for the assay. A serial dilution of the working solution was then utilized to obtain various
protein concentrations for the standard curve. In order to determine the quantity of
protein in each sample, an aliquot (5 μl) or a dilution, was added to 795 μl of water in a
12x75 mm tube with four replicates. Following dilution of the sample in water, BioRad
protein assay dye (200 μl) was added to all the tubes to obtain a total volume of 1 ml.
After addition of the dye, the standards and samples were vortexed and allowed to
incubate at room temperature for 5 min. Absorbance was read at 595 nm using the
Versamax spectrophotometer (Molecular Devices, Sunnyvale, CA) with 200 μl of each
sample in a 96 well plate. The SpotMax software allowed determination of protein
content of the samples based on optical density values from the standard curve.

3.8 Western analysis
The expression of specific proteins was identified in cytosolic extracts of cells
using SDS-PAGE. Equal quantities (20-150 μg/well) of proteins from treated cells were
loaded onto a 12.5% gel (10% for NMDAR1 analysis), which was subjected to
electrophoresis according to the method of Laemmli (1970). The proteins were then
electro-transferred from the gel to a nitrocellulose membrane (VWR, Westchester, PA).
Staining with 0.1% Ponceau S was used to assess efficiency of transfer. After blocking
with 5% non-fat dry milk for 1 h, the membranes were incubated overnight with primary
antibody (Cell Signaling, Beverly, CA) raised against caspase-3 (1:2000) or cleaved
caspase-3 fragments (1:1000). Membranes were incubated separately in primary
antibody against proteins regulated by NFκB involved in the apoptotic process including
bcl-xL (1:200; Santa Cruz Biotechnology Inc., Santa Cruz, CA), bcl-2 (1:1000; Upstate
Biotechnologies, Charlottesville, VA) or the proapoptotic protein bax (1:500, Santa Cruz,
Santa Cruz, CA). In addition, the levels of the endogenous antioxidant enzymes
(MnSOD, 1:2500; Cu/ZnSOD, 1:1000; Upstate Biotechnologies, Charlottesville, VA) and
the differentiation marker NMDAR1 (1:750; Chemicon International, Temecula, CA)
were assessed. In order to evaluate RARα-dependent modulation of gene expression,
we used primary antibody against cellular retinoic acid binding protein 2 (1:10000;
Novus Biologicals Inc., Littleton, CO). Finally, membranes were incubated in antibodies
33

against AKT proteins [phospho-AKT (Ser473), 1:1000; Cell Signaling Technology Inc.,
Danver, MA; total-AKT(B-1), 1:2000; Santa Cruz Biotechnology Inc., Santa Cruz, CA] to
assess alteration in the prosurvival factors in response to ATRA exposure.
On the following day membranes were washed twice for 7 min with TBST (10
mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 8.0) and incubated with a horseradish
peroxidase conjugated secondary antibody (1:3000; Santa Cruz, Santa Cruz, CA). This
procedure was followed by three 5 min washes in TBST and another in TBS (TBST
without Tween-20). The proteins bound to each antibody were then visualized through
the enhanced chemiluminescence system (Amersham Biosciences, Piscataway, NJ).
Analysis of the levels of glyceraldehye 3-phosphate dehydrogenase (GAPDH; 1:10000;
Trevigen, Gaithersburg, MD) protein was used to normalize protein loading, as GAPDH
is not affected by any of the treatments. The intensity of the specific protein bands was
quantified by densitometric analysis using the Quantity One software (Biorad, Hercules,
CA) and the results are reported as percent change in levels of specific protein versus
control.

3.9 Caspase-3 protease activity assay
Caspase-3 activity in the samples was assessed by proteolytic cleavage of the
fluorophore 7-amino-4-trifluoromethyl coumarin (AFC) from the substrate conjugate,
DEVD-AFC (ApoAlert assay kit; Clontech Laboratories, Palo Alto, CA). SK-N-SH cells
were plated at a density of 1x 106 cells/p150 plate. Following previously mentioned
treatments cells were lysed on ice and centrifuged (14,000 rpm for 10 min, Eppendorf
centrifuge 5417R). An equal volume (50 μl) of the supernatant of each sample was
incubated with DEVD-AFC in the presence of 10 mM dithiothreitol, for 1 h at 37°C. AFC
was detected using a 400-nm excitation filter and a 505 nm emission filter by means of
the Gemini XPS fluorescent microplate reader (Molecular Devices, Sunnyvale CA)
equipped with SoftMax Pro software. The data obtained was normalized to protein
content measured with the BioRad protein assay. The results are reported as fold
change in caspase-3 activity versus control and are representative of 5 individual
experiments.
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3.10 CellTiter-Glo luminescent cell viability assay
The viability of the SK-N-SH cells was quantitated using ATP dependent
luciferase activity (CellTiter-Glo Luminescent Cell Viability Assay, Promega, Madison,
WI) in 96-well plates. The cells were seeded in growth medium (2 x 10 3/well; 5
wells/sample) and treated as previously described. Luminescence was measured using
the Centro LB 960 microplate luminometer (Berthold Technologies USA LLC, Oak
Ridge, TN). The data was acquired using the Mikrowin 2000 software and reported as a
percent change in luminescence.

3.11 SOD2 siRNA transfection
Small interfering RNA (siRNA) against the human SOD2 gene was used to
reduce expression of MnSOD in SK-N-SH cells. The cells were plated at a density of 9 x
105 cells in 100 mm cell culture dishes. On the following day cells were transfected with
SOD2 siRNA (100 nM; ON-TARGET plus SMART pool, Dharmacon Inc, Chicago, IL)
using RNAi fect transfection reagent (Qiagen, Valencia, CA). Control siRNA (100 nM;
siCONTROL non-targeting siRNA, Dharmacon Inc, Chicago, IL) was used to
demonstrate that introduction of non-specific siRNA had no effect on MnSOD
expression in the SK-N-SH cells. The siRNA transfected cells were then exposed to the
various agents including ATRA (10 μM) and CDDP (10 μM) as outlined previously.
Following treatments the cells were collected, lysed on ice and centrifuged (14,000 rpm
for 10 min). The supernatants were then analyzed for activity and protein expression of
caspase-3 and MnSOD.

3.12 Luciferase activity assay
In order to determine RARE dependent transcriptional activation in the presence
of the retinoic acid receptor-α dominant negative (dnRARα; gift of Dr. Ajay Rana) we
conducted double transfection experiments. The SK-N-SH cells were plated (3 x
106/p100 plate) and transfected with the RARE-Control (RCt) or RARE-Luciferase (RLu)
vector (20 µg each; Panomics Inc., Fremont, CA). Additional plates were co-transfected
with either the psG5 or dnRARα vectors (40 µg each) along with those previously
mentioned.
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We also transfected cells (3 x 106 /p100 plate) with either the empty vector or the
NFκB reporter construct (6 µg each; Panomics Inc., Fremont, CA) in order to determine
whether the transcription factor mediates CDDP-dependent increase in MnSOD
expression. A modification of the calcium phosphate method was used to carry out
transfection of the vectors as described (Graham et al., 1973). The cells were
trypsinized and re-plated for the luciferase assay the next day in 24 well plates (1.5 x
105 cells /well). On the following day the cells were exposed to either ATRA (10 µM) or
CDDP (0-25 μM). At the end of the treatment, the cells were lysed in reporter lysis
buffer and analyzed for luciferase activity using the Luciferase Assay System (Promega)
in a TD-20/20 luminometer (Turner Designs).

3.13 Superoxide Dismutase (SOD) Activity Assay
In order to analyze MnSOD activity, the SK-N-SH cells were plated at a density of
1 x 106 cells/p150 plate. After 24 h, the cells were exposed to various CDDP
concentrations (0-25 μM).

Following a 24 h, treatment with CDDP the cells were

harvested in media and centrifuged at 1500 rpm in a Sorvall Legend RT centrifuge for
10 min at 4°C. The pellets were then washed twice in cold PBS (pH 7.4). SOD activity
was measured in whole cell lysates by the method of Spitz and Oberley, (1989) using
indirect competition between SOD and nitroblue tetrazolium, for superoxide produced
by xanthine/xanthine oxidase. The activity of MnSOD was measured utilizing sodium
cyanide-dependent inhibition of Cu/ZnSOD. The data was normalized to protein content
and is reported as fold change in activity as compared to untreated cells.

3.14 Isolation of mRNA
In order to isolate RNA, SK-N-SH cells were plated (1 x 106/p150 plate) and
treated on the next day with CDDP (5, 10 or 25 μM) for 24 h. The cells were then
washed twice with cold PBS containing 0.1% diethylpyrocarbonate (DEPC) followed by
addition of 1.5 ml TriReagent (Sigma, St. Louis, MO). The cells in TriReagent were
transferred into RNase free tubes and centrifuged at 12,000 rpm for 10 min at 4°C. The
supernatant was transferred to another set of RNase free tubes, and allowed to stand
for 5 min at room temperature. Chloroform (300 μl) was added to each tube and mixed
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for 15 sec. After centrifugation (12,000 rpm, 15 min, 4°C) the supernatant was mixed
with 750 μl 100% isopropanol and allowed to stand at room temperature for 10 min.
After centrifugation (7,500 rpm, 5 min, 4°C) the pellets were washed with 75% ethanol
in DEPC water (200 μl), dried and reconstituted in RNase free water.

The RNA

concentration was determined spectrophotometrically and the quality determined using
the Agilent 2100 Bioanalyzer utilizing the RNA 6000 NanoAssay Kit (Agilent
Technologies, Palo Alto, CA).

3.15 Real time RT-PCR
The SK-N-SH cells were plated at 1 x 106 cells/p150 plate and exposed to
various CDDP concentrations (0-25 μM) for 24 h. Total mRNA was isolated from the
treated cells as described above. MnSOD mRNA relative levels were determined by
quantitative RTPCR using Taqman Universal PCR Master Mix and primers from Applied
Biosystems (Assay ID#HS00167309 MnSOD).
GAPDH) were used to normalize the data.

Primers for GAPDH (ID#4326317E
Optimal primer concentrations were

determined to be 200 ng/μl with the total RNA concentration in the quantitative RTPCR
reaction being 20 ng/μl. The ABI 7700 Sequence Detection System was used with the
thermocycler programmed as follows: 48°C for 30 min; 95°C for 10 min; then 40 cycles
of 95°C for 15 sec and 60°C for 1 min.

3.16 Statistical analysis
The results were statistically analyzed using the SigmaStat software (SPSS, Inc.
Chicago, IL). Statistical significance was assessed with analysis of variance and a post
hoc Student Newman Keul’s test at a 95% confidence interval.
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CHAPTER IV – RESULTS
STUDY OF ATRA-INDUCED CHEMORESISTANCE

4.1 CDDP decreases viability in SK-N-SH cells in a concentration dependent
manner
Initial experiments were conducted to determine the effect of a 24 h exposure to
CDDP (0-25 μM) on the viability of SK-N-SH cells using the 3-(4,5-dimethylthiazolyl-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. This cytotoxicity assay involves
cleavage of pale yellow MTT into blue formazan crystals by the succinate-tetrazolium
reductase system predominantly of the mitochondrial respiratory chain (Mosmann,
1983). The enzyme system is active only in viable cells, allowing quantitation of those
that survive exposure to the chemotherapeutic agent. In Fig. 4.1 we illustrate that CDDP
exposure significantly decreased viability of the SK-N-SH cells with increasing
concentrations wherein 25 μM reduced survival by approximately 40%.

Figure 4.1 CDDP decreases viability in SK-N-SH cells in a concentration
dependent manner
MTT assay to determine cell survival in SK-N-SH cells exposed to a range of CDDP
concentrations (0-25 µM) for 24 h. Survival of the SK-N-SH cells decreased with
increasing concentration with significant differences at 5, 10 and 25 µM CDDP. The
results are representative of five independent experiments expressed as mean ± S.E.M
(*p<0.001 vs. control).
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4.2 Acute ATRA pretreatment attenuates CDDP-induced caspase-3 cleavage and
activity in SK-N-SH cells
Activation of caspase-3, a critical executioner protein of apoptosis, has been
used as an indicator of cytotoxicity (Slee et al., 2000). In order to determine whether an
acute ATRA pretreatment of 24 h would cause resistance to CDDP in neuroblastoma,
we assessed caspase-3 cleavage (western analysis) and activity in SK-N-SH cells. In
accordance, we pretreated SK-N-SH cells with 10 μM ATRA for 24 h followed by CDDP
(10-25 μM) for the next day while continuing with exposure to the retinoid. We used
dimethy sulfoxide (DMSO) as the vehicle for ATRA maintaining the concentration
(0.05%) in all of the samples tested.
Treatment with ATRA (10 μM) alone did not result in caspase-3 cleavage (Fig.
4.2A; lower panel, lane 2) suggesting that the retinoid does not have cytotoxic effects on
the SK-N-SH cells at the concentration used. Exposure to CDDP (10-25 μM) resulted in
caspase-3 cleavage, as observed by the appearance of the 17 and 19 kDa fragments,
(Fig. 4.2A; lower panel, lanes 3 and 5). A decrease in the expression of the parental
caspase-3 protein paralleled the increase in cleavage with CDDP treatments (Fig. 4.2A;
middle panel lanes 3 and 5). A 24 h pretreatment with 10 μM ATRA followed by 10-25
μM CDDP for an additional 24 h resulted in a decrease in caspase-3 cleavage (Fig.
4.2A; lower panel, lanes 4 and 6) compared to CDDP alone demonstrating the induction
of chemoresistance by the retinoid.
Following the caspase-3 cleavage studies, we evaluated activity of the enzyme to
determine whether it correlated with the western analysis. Consistent with the westerns,
ATRA treatment (10 μM) did not alter caspase-3 activity compared to control. Exposure
to CDDP (10-25 μM) for 24 h significantly increased caspase-3 activity, which was
attenuated by acute pretreatment (one day) with 10 μM ATRA by approximately 40-50%
(Fig. 4.2B) confirming that acute incubation with the retinoid induces chemoresistance in
the SK-N-SH cell line.
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Figure 4.2 Acute ATRA pretreatment attenuates CDDP-induced caspase-3 cleavage and
activity in SK-N-SH cells
(A) Western blot analysis of cleaved caspase-3 in 75 µg of cytoplasmic extracts of SK-N-SH
cells receiving either DMSO (vehicle), ATRA, CDDP or a combination of the latter two. A 24 h
pretreatment with ATRA attenuates CDDP-induced caspase-3 cleavage in SK-N-SH cells.
Densitometric analysis of 5 independent experiments is expressed as mean ± S.E.M. (*p<0.05
vs. control; § p<0.05 vs. CDDP. GAPDH was used as a loading control). (B) Caspase-3 activity
was determined using the ApoAlert fluorescence assay in SK-N-SH cells 24 h after exposure to
treatments as indicated. A pretreatment with ATRA attenuates CDDP-induced caspase-3
activity in SK-N-SH cells. The data was normalized to protein content (Biorad assay) and is
expressed as mean ± S.E.M. of 5 independent experiments (*p<0.001 vs. control; § p<0.05 vs.
corresponding CDDP control).

40

4.3 Chemical interaction with CDDP has a limited role in ATRA-induced
chemoresistance
Analysis of the chemical structures of ATRA and CDDP (Fig. 4.3A) suggested
that the retinoid could chemically interact with the antineoplastic agent limiting its ability
to induce cytotoxicity. To investigate the possibility of a chemical interaction between
ATRA and CDDP reducing cytotoxicity we carried out treatments in SK-N-SH cells as
mentioned previously. In addition we treated cells with ATRA for 24 h, following which
we replaced the retinoid containing media with 10 μM CDDP for the next day. Along
with this we exposed a set of plates to ATRA for 24 h and replaced the media the next
day which constituted the negative control.
Western analysis of cytoplasmic extracts of the treated cells for caspase-3
cleavage indicated that ATRA did not alter the pro-apoptotic protein as compared to the
control samples (Fig. 4.3B; lower panel, lanes 2 and 3). In contrast to this, exposure to
CDDP resulted in the appearance of the caspase-3 cleavage products (Fig. 4.3B; lower
panel, lane 4), consistent with the activity assay. Furthermore, it can be seen that a 24 h
ATRA treatment followed by CDDP alone attenuated caspase-3 cleavage similar to
continued retinoid exposure along with the chemotherapeutic (Fig. 4.3B; Lower panel;
lane 5, 6). The experiment was repeated in triplicate with the same result, which
suggests that a chemical interaction of ATRA with CDDP has limited contribution to the
retinoid-induced chemoresistance.
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Figure 4.3 Chemical interaction with CDDP has a limited role in ATRA-induced
chemoresistance
(A) Chemical structures of ATRA and CDDP. (B) Western blot analysis of cytoplasmic
extracts (75 µg protein loaded per sample) of SK-N-SH cells treated with DMSO, ATRA,
CDDP or both the retinoid and the chemotherapeutic agent as indicated on days 1 and
2. Cytoplasmic extracts of the cells were collected after the 24 h incubation with CDDP.
A 24 h pretreatment with ATRA alone followed by CDDP produced chemoresistance
similar to continued retinoid exposure along with the anticancer agent. Therefore,
chemical interaction with CDDP contributes to a minor extent to the acute ATRAinduced chemoresistance.
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4.4 Prior ATRA treatment attenuates prolonged CDDP exposure dependent
caspase-3 activity in SK-N-SH cells
Having demonstrated that chemoresistance occurred with acute ATRA
pretreatment, we conducted studies to better represent clinically used dosing regimens
(Berthold and Hero, 2000). The experiments were designed using lower concentrations
of CDDP (0.5 or 1 μM) for 24 – 96 h in the presence or absence of ATRA following 24 h
of pretreatment with the retinoid.
Exposure to ATRA (10 μM) alone had no effect on caspase-3 activity at any of
the time points tested. Treatment with CDDP (0.5 or 1.0 μM) on the other hand,
significantly increased caspase-3 activity in all tests, which was augmented
approximately 2 fold with the higher concentration of the antineoplastic agent at the 24
and 48 h time points alone (Fig. 4.4A-D). Prolonged (96 h) exposure to CDDP resulted
in an approximately 50% reduction in caspase-3 activity in the SK-N-SH neuroblastoma
cells when compared to a 24 and 48 h treatment (Fig. 4.4A-D). Furthermore, we
demonstrate that even in the presence of a reduced response to CDDP, an acute ATRA
pretreatment attenuated caspase-3 activity dependent on the antineoplastic agent at all
time points (24, 48, 72 and 96 h), confirming that a 24 h exposure to the retinoid
induces chemoresistance (Fig. 4.4A-D).
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Figure 4.4 Prior ATRA treatment attenuates prolonged CDDP exposure dependent
caspase-3 activity in SK-N-SH cells
(A) Caspase-3 activity was determined using the ApoAlert fluorescence assay in SK-N-SH cells
exposed to DMSO, ATRA, CDDP or the latter two together at various time points as indicated.
Acute ATRA pretreatment attenuates CDDP-induced caspase-3 activity in SK-N-SH cells at 24
h (*p<0.001 vs. control; § p<0.001 vs. CDDP) (B) 48 h (*p<0.05 vs. control; § p<0.05 vs. CDDP)
(C) 72 h (*p<0.05 vs. control; § p<0.05 vs. CDDP) and (D) 96 h (*p<0.001 vs. control; § p<0.001
vs. CDDP). The data was normalized to protein content (Biorad assay) and is expressed as
mean ± S.E.M. of 5 independent experiments.
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ROLE OF NFκB IN ATRA-INDUCED CHEMORESISTANCE

4.5 ATRA pretreatment attenuates CDDP-induced decrease in expression of bcl-xL
in SK-N-SH cells
Manytmaa et al., (2000), have demonstrated that retinoids generate reactive
oxygen species (ROS) including hydrogen peroxide as determined by flow cytometry
using dichlorofluorescin diacetate (DCFH-DA). The resultant alteration in the redox
status of the cell can activate transcription factors including NFκB which has been
suggested to contribute to chemoresistance (Takada et al., 2003; Yeh et al., 2003).
Therefore, in order to identify potential mediators of ATRA-induced resistance, we
investigated the expression of NFκB target genes involved in the apoptotic process
including bcl-xL, bcl-2 and bax (Catz and Johnson, 2001; Huerta-Yepez et al., 2004;
Grimm et al., 2005). For this set of experiments we plated SK-N-SH cells and exposed
them the following day to ATRA (10 µM) for 24 h. We then treated the cells with CDDP
(10 µM) in the presence or absence of ATRA (10 µM) and harvested them after 24 h.
Cytosolic fractions of SK-N-SH cells were found to exhibit detectable levels of bclxL (Fig. 4.5; lane 1). Exposure to ATRA increased the expression of bcl-xL by
approximately 80% as seen in lane 2 of figure 4.5. A 24 h treatment with CDDP caused
a 20% reduction in the expression of bcl-xL as compared to the vehicle treated cells
(Fig. 4.5; lane 3 versus lane 1). Furthermore, a 24 h ATRA pretreatment significantly
attenuated the decrease in bcl-xL caused by CDDP exposure in the SK-N-SH cells (Fig.
4.5; lane 4). This observation suggests that the antiapoptotic bcl-xL may contribute to
ATRA-induced chemoresistance.
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Figure 4.5 ATRA pretreatment attenuates CDDP-induced decrease in expression
of bcl-xL in SK-N-SH cells
Western blot analysis of the anti-apoptotic protein bcl-xL in cytoplasmic extracts of SKN-SH cells exposed to CDDP in the presence or absence of ATRA pretreatment (75 µg
of protein loaded per sample). Incubation with ATRA increased bcl-xL levels in SK-N-SH
cells. Exposure to CDDP for 24 h decreased bcl-xL which was attenuated by prior ATRA
treatment (*p<0.001 vs. control; §p<0.05 vs. CDDP). Densitometric analysis of the data
is expressed as mean ± S.E.M of 5 independent experiments. GAPDH was used as the
loading control.
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4.6 ATRA pretreatment has no effect on CDDP-induced decrease in bcl-2 in SK-NSH cells
The antiapoptotic bcl-2 has been demonstrated to confer resistance to
chemotherapy and radiation (Weller et al., 1995). In order to explore the possible
involvement of the protein bcl-2 in chemoresistance on ATRA pretreatment, we
analyzed expression of the antiapoptotic protein by western analysis. As can be
observed in Fig. 4.6, both ATRA and CDDP treatment reduced the expression of bcl-2
by approximately 20-30% in the SK-N-SH cells suggesting that the anti-apoptotic
protein may not contribute to the observed chemoresistance. In addition, ATRA
pretreatment of 24 h did not alter the observed CDDP-induced decrease in bcl-2,
confirming that the proto-oncogene has no contribution to retinoid-dependent
chemoresistance in the SK-N-SH cells under these experimental conditions.

Figure 4.6 ATRA pretreatment has no effect on CDDP-induced decrease in bcl-2 in
SK-N-SH cells
Western blot analysis of the antiapoptotic protein bcl-2 in cytoplasmic extracts of CDDP
treated SK-N-SH cells, some of which were pretreated with ATRA (75 µg of protein
loaded per sample). Exposure to both ATRA (48 h) and CDDP (24 h) significantly
decreased bcl-2 expression in the SK-N-SH cells. The CDDP-dependent decrease in
bcl-2 remained unaltered with acute ATRA pretreatment. The results are expressed as
mean ± S.E.M of 3 independent experiments (*p<0.05 vs. control). GAPDH was used as
the loading control.
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4.7 ATRA pretreatment attenuates CDDP-induced increase in expression of bax
in SK-N-SH cells
Bax is one of the proapoptotic members of the bcl-2 family, the deficiency of
which is found to attenuate apoptosis and contribute to resistance (McCurrach et al.,
1997). As seen in Fig. 4.7, the expression of bax remained unaltered with ATRA
treatment when compared to vehicle treated SK-N-SH cells (Fig. 4.7; lane 2). Following
a 24 h treatment with CDDP, SK-N-SH cells expressed higher levels (approximately 3
fold increase) of bax as compared to both vehicle and ATRA exposure (Fig. 4.7; lane 3).
ATRA pretreatment (24 h), on the other hand, was found to attenuate CDDP-induced
increase in the expression of bax by approximately 50% in the SK-N-SH cells (Fig. 4.7;
lane 4) suggesting that the decrease of the proapoptotic protein may contribute to the
observed retinoid-induced chemoresistance.

Figure 4.7 ATRA pretreatment attenuates CDDP-induced increase in expression
of bax in SK-N-SH cells
Western blot analysis of the proapoptotic protein bax in the SK-N-SH cell line treated
with ATRA or CDDP as indicated (75 µg of protein loaded per sample). Exposure to
CDDP for 24 h significantly increased the expression of bax which was attenuated by
acute ATRA pretreatment. The results are expressed as mean ± S.E.M of 3
independent experiments (*p<0.05 vs. control; §p<0.05 vs. CDDP). GAPDH was used
as the loading control.
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4.8 ATRA pretreatment enhances MnSOD levels in CDDP treated SK-N-SH cells
Besides regulating proteins of the apoptotic cascade, NFκB is essential for the
induction of the endogenous antioxidant manganese superoxide dismutase (MnSOD)
by differentiating agents including PMA and cytokines such as TNFα and IL-1β
(Kiningham et al., 2001). The NFκB-dependent expression of MnSOD protected
adenocarcinoma from TNFα-induced cytotoxicity (Delhalle et al., 2002). In addition,
preservation of MnSOD in response to ATRA exposure conferred resistance to induced
apoptosis in acute myeloblastic leukemia (Mantymaa et al., 2000). In view of these
reports, we determined whether MnSOD contributed to the observed ATRA-induced
chemoresistance in the SK-N-SH cell line. In Fig. 4.7 we show that both ATRA and
CDDP increased expression of MnSOD in the SK-N-SH cells by approximately 2 fold
(Fig. 4.7; lanes 2 and 3). Furthermore, ATRA pretreatment enhanced CDDP-dependent
MnSOD expression in SK-N-SH cells by approximately 20% (Fig. 4.7; lane 4). This
observation suggests that increased MnSOD expression, generated in response to
treatment with both ATRA and CDDP, may attenuate mitochondrial damage and
contribute to retinoid-induced chemoresistance.
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Figure 4.8 ATRA pretreatment enhances MnSOD levels in CDDP treated SK-N-SH
cells
Western blot analysis of the endogenous antioxidant MnSOD in CDDP treated SK-N-SH
cells with or without ATRA pretreatment (75 µg of protein loaded per sample). Exposure
to both ATRA and CDDP significantly increased MnSOD expression in the SK-N-SH
cells. An acute ATRA pretreatment significantly enhanced the CDDP-dependent
increase in MnSOD (*p<0.001 vs. control; §p<0.05 vs. CDDP). Densitometric analysis
of the data is expressed as mean ± S.E.M of 5 independent experiments. GAPDH was
used as the loading control.
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4.9 SN50 inhibition of NFκB attenuates ATRA-mediated expression of MnSOD and
NMDAR1
Subsequent to analyzing changes in expression of NFκB target genes, we used
the SN50 inhibitor peptide to elucidate the contribution of the pro-survival transcription
factor in acute ATRA pretreatment-dependent chemoresistance. In order to verify that
activation of the NFκB pathway was reduced by SN50, we evaluated the expression of
two known target genes of the transcription factor, MnSOD and the differentiation
marker N-methyl-D-aspartate receptor subunit 1 (NMDAR1) (Warner et al., 1996; Begni
et al., 2003). Both are readily upregulated in the presence of ATRA as recently reported
(Mantymaa et al., 2000; Varju et al., 2001; Kiningham et al., 2008).
To carry out the study, we treated SK-N-SH cells with 10 μM ATRA, with or
without 5 μg/ml SN50. The inhibitor peptide SN50 binds to the nuclear localization
sequence of the NFκB subunit p50 and concentration dependently inhibits translocation
of the active transcription factor complex p50-p65 into the nucleus which alters the
expression of target genes (Lin et al., 1995). Cytoplasmic fractions were collected after
48 h of treatment and were then analyzed for MnSOD and NMDAR1 protein by western
analysis. The SN50 inhibitor peptide (5 μg/ml) reduced the basal levels of the
endogenous antioxidant in the SK-N-SH cells (approximately 30%) and completely
abolished the ATRA dependent increase in the expression of MnSOD (Fig. 4.9A; lanes
3 and 4). This data validates the contribution of NFκB in ATRA-mediated regulation of
the primary antioxidant.
The differentiation marker NMDAR1 was detectable in the SK-N-SH cells
exposed to ATRA (10 μM) for 48 h, which was much lower in the vehicle treated cells
(Fig. 4.9B; lanes 2 and 1). An incubation of the cells with SN50 inhibitor peptide did not
alter basal NMDAR1 expression, but attenuated the ATRA-dependent increase
(approximately 6 fold) by approximately 30% (Fig. 4.9B; lanes 3 and 4). This data
suggests that NFκB contributes at least in part, to the retinoid dependent increase in
NMDAR1 expression, thereby playing a role in ATRA-mediated differentiation in the SKN-SH cells.
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Figure 4.9 SN50 inhibition of NFκB attenuates ATRA-mediated expression of
MnSOD and NMDAR1
(A) Western blot analysis of MnSOD in SK-N-SH cells receiving ATRA (10 µM), SN50
(5 µg/ml) or both. Protein (50 µg) isolated from cytoplasmic fractions collected 48 h after
treatment was analyzed with GAPDH as a loading control. Results are expressed as
mean ±S.E.M from 3 independent experiments (*p<0.05 vs. control; §p<0.05 vs. ATRA).
(B) Western blot analysis of cells exposed to either 0-10 μM ATRA or 5 μg/ml SN50 or a
combination of both. Protein (150 μg) isolated from cytoplasmic fractions collected after
48 h of treatment was examined for NMDAR1 with GAPDH as a loading control. Results
are expressed as mean ± S.E.M from 3 independent experiments (*p<0.001 vs. control;
§p<0.05 vs. ATRA).
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4.10 SN50 inhibition of NFκB attenuates acute ATRA-mediated chemoresistance
to CDDP in the SK-N-SH cells
The results from Fig. 4.9 suggest that the SN50 inhibitor peptide can suppress
ATRA-induced changes mediated through NFκB. Following this we employed SN50 (10
µg/ml) to enable us to establish the contribution, if any, of the NFκB transcription factor
in retinoid-induced resistance to CDDP. The inhibitor peptide was used at a higher
concentration as compared to the previous experiment to achieve enhanced
suppression of NFκB as observed in preliminary data (not shown). In order to explore
the possible role of NFκB in chemoresistance we used the Cell Titer-Glo luminescent
viability assay that quantitates ATP present, signaling metabolically active cells. We
demonstrate that exposure to CDDP leads to a concentration dependent decrease in
luminescence of the SK-N-SH cells (Fig. 4.10A and B). As with earlier experiments,
prior exposure to ATRA attenuated the CDDP-induced decrease in viability consistent
(Figs. 4.10A and B). In addition, SN50 (10 µg/ml) attenuated (by approximately 5-10%)
CDDP-dependent reduction in luminescence (Figs. 4.10A and B: bars 3 versus 7) which
could interfere with the observation of chemoresistance. Moreover, although incubation
with SN50 attenuated the ATRA-dependent chemoresistance, there was no difference
between the samples exposed to both the retinoid and CDDP in presence or absence of
the inhibitor peptide. Taken together the results suggest that NFκB activation by ATRA
does not contribute to the acute retinoid pretreatment mediated chemoresistance in the
SK-N-SH human neuroblastoma cells.
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Figure 4.10 SN50 inhibition of NFκB attenuates acute ATRA-mediated
chemoresistance to CDDP in the SK-N-SH cells
(A) Luminescent ATP-dependent viability carried out in ATRA or CDDP (10 µM) treated
SK-N-SH cells incubated with or without SN50 inhibitor peptide (10 µg/ml) as indicated.
SN50 inhibition of NFκB attenuates acute ATRA-mediated chemoresistance to CDDP in
the SK-N-SH cells. Experiments were carried out in 96 well plates with 5 replicates per
sample. The data is represented as the mean ±S.E.M from 5 independent experiments.
(*p<0.001 vs. control; § p<0.05 vs. CDDP). (B) Cell titer glo luminescent assay
conducted in ATRA (10 µM) or CDDP (25 µM) treated SK-N-SH cells incubated with
either vehicle or SN50. Inhibition of NFκB by SN50 attenuates acute ATRA-mediated
chemoresistance. Experiments were carried out in 96 well plates with 5 replicates per
sample. The data is represented as the mean ± S.E.M from 5 independent experiments.
(*p<0.001 vs. control; § p<0.05 vs. CDDP).
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ROLE OF MnSOD IN ATRA-INDUCED CHEMORESISTANCE

4.11 SOD2 siRNA attenuates CDDP dependent increase in caspase-3 cleavage
and activity in SK-N-SH cells
Studies have shown that MnSOD can diminish CDDP induced apoptosis in
human embryonic kidney cells and squamous cell carcinoma (Davis et al., 2001, Ueta
et al., 2001). Moreover, ATRA was demonstrated to attenuate staurosporine-induced
apoptosis through preservation of MnSOD in primary cultures of rat neonatal
hippocampus (Ahlemeyer et al., 2001). We therefore employed SOD2 siRNA to define
the function of MnSOD in acute ATRA pretreatment mediated chemoresistance.
Transfection of the SK-N-SH cells with SOD2 siRNA (100 nM) for 24 h caused a
substantial reduction in MnSOD expression when compared to the negative control (Fig.
4.11A; middle panel, lanes 5-8 vs. lanes 1-4). Coincident with the decrease in MnSOD
expression we noticed a reduction in caspase-3 cleavage in CDDP treated cells
transfected with SOD2 versus control siRNA (Fig. 4.11A; lower panel, lane 7 vs. 3).
Correspondingly there was a significant decrease in caspase-3 activity in cells
incubated with SOD2 siRNA and exposed to CDDP as compared to the negative control
(cells receiving control siRNA along with the antineoplastic agent) (Fig.4.11B). The
reduction in CDDP-induced caspase-3 activity with SOD2 siRNA suggests that MnSOD
contributes to cytotoxicity induced by the anticancer agent in this model.
A reduction in MnSOD expression by the presence of SOD2 versus control
siRNA had no effect on acute ATRA pretreatment mediated chemoresistance indicated
by unaltered caspase-3 cleavage (Fig. 4.11A; lower panel, lane 8 vs. 4). Similarly
incubation

with

SOD2

siRNA

was

unable

to

attenuate

the

ATRA-induced

chemoresistance observed in cells receiving the control siRNA. This is indicated by the
absence of a significant difference between the ATRA and CDDP treated cells
transfected with either control or SOD2 siRNA (Fig.4.11B; last 2 bars) eliminating the
possible role of MnSOD in retinoid-induced chemoresistance at this time point.

55

A

B

Figure 4.11 SOD2 siRNA attenuates CDDP dependent increase in caspase-3
cleavage and activity in SK-N-SH cells
(A) Western blot analysis for MnSOD and cleaved caspase-3 in ATRA or CDDP treated
cells incubated with either control or SOD2 siRNA as indicated. A reduction in MnSOD
attenuates CDDP dependent increase in caspase-3 cleavage in SK-N-SH cells. (B)
Fluorimetric caspase-3 activity assay was conducted in SK-N-SH cells incubated with
either control or SOD2 siRNA treated with ATRA or CDDP as indicated. Incubation with
SOD2 siRNA attenuates CDDP dependent increase in caspase-3 activity in SK-N-SH
cells. The data was normalized to protein content and expressed as mean ± S.E.M
(*p<0.01 vs. control; § p<0.01 vs. control siRNA CDDP; Φp<0.01 vs. CDDP).
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ROLE OF RETINOIC ACID RECEPTOR α (RARα) IN ATRA-INDUCED
CHEMORESISTANCE

4.12 RARα dominant negative (dnRARα) prevents retinoic acid response element
(RARE) dependent luciferase activity
The metabolites of vitamin A including ATRA are known to exert their effects
through interaction with nuclear retinoic acid receptors α, β and γ which are recognized
to form heterodimers with the rexinoid receptors (Laudet and Gronemeyer, 2002). The
RARα isoform, based on luciferase assays, is the most potent inducer of ATRA
mediated transcription in COS-7 cells (Idres et al., 2002; Kitanaka et al., 1997). In view
of the robust RARα mediated transcriptional activation by ATRA, we targeted the alpha
isoform to determine whether the retinoid receptor played a role in the observed
phenomenon of chemoresistance.
In the first experiment in this set, we evaluated whether dnRARα could attenuate
retinoic acid response element (RARE) dependent luciferase activity using double
transfection experiments. A 24 h exposure to ATRA significantly increased luciferase
activity in cells transfected with the RARE luciferase reporter as compared to the control
(Fig.4.12A; bar 2 versus 1). The co-transfected control-psG5 vector did not alter ATRAdependent increase in luciferase activity as can be observed in the next 2 bars of Fig.
4.11. Finally, cotransfecting in the dnRARα containing vector significantly attenuated the
ATRA dependent RARE luciferase activity (Fig.4.12A; last 2 bars). The results from this
experiment indicate that the dominant negative successfully blocked RARE-mediated
transcriptional activity.
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Figure 4.12 RARα dominant negative (dnRARα) prevents retinoic acid response element
(RARE) dependent luciferase activity
(A) Luciferase reporter activity in SK-N-SH cells transfected with vectors as indicated and
treated with either DMSO (0.05%) or 10 µM ATRA. Transfection with dnRARα prevented ATRAinduced RARE dependent luciferase activity. The data was normalized to DMSO treated cells
and is reported as mean ± S.E.M of 4 independent experiments (*p<0.001 vs control; §p<0.001
vs RLu-psG5).

In order to validate the results of the luciferase assay (Fig. 4.12A), we analyzed
the expression of cellular retinol binding protein 2 (CRABP2), a transcriptional target of
RARα (Redfern et al., 1994), in cells transfected with either psG5 or dnRARα vector and
exposed to DMSO or ATRA (10 µM). In addition, we evaluated the levels of MnSOD,
which we have recently demonstrated is upregulated in response to ATRA (10 µM)
treatment (Kiningham et al., 2008). As can be observed in Fig.s 4.12B and C ATRA
exposure produced a striking increase in the expression of both CRABP2 and MnSOD
in SK-N-SH cells transfected with the control psG5 vector. Incubating the cells with the
dnRARα attenuated ATRA-dependent expression of both proteins (CRABP2 by
approximately 20% and MnSOD by about 50%). These results establish that the
dnRARα altered, in part, the RARE-dependent regulation of protein expression.
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Figure 4.12(B) Western blot analysis of CRABP2 in cytosolic extracts (75 µg protein) of
SK-N-SH cells transfected with vectors as indicated and exposed to DMSO or 10 µM
ATRA. Retinoid-dependent increase in CRABP2 was attenuated by dnRARα. GAPDH
was used as the loading control. The data is reported as mean ± S.E.M of 4
independent experiments (*p<0.001 vs. psG5 control; §p<0.05 vs. psG5 ATRA). (C)
Western blot analysis of MnSOD in cytosolic extracts (75 µg protein) of SK-N-SH cells
transfected with either the psG5 or dnRARα vectors and treated with DMSO or ATRA
(10 µM). The increase in MnSOD in SK-N-SH cells in response to ATRA was attenuated
by incubation with dnRARα. GAPDH was used as the loading control. The data is
reported as mean ± S.E.M of 4 independent experiments (*p<0.001 vs. psG5 control;
§p<0.05 vs. psG5 ATRA).
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4.13 RARα does not contribute to acute ATRA pretreatment mediated
chemoresistance
After demonstrating that the dnRARα could attenuate RARE-dependent luciferase
activity and ATRA-induced gene expression we assessed the samples for capase-3
activity to delineate the role of the retinoid receptor in the observed chemoresistance.
We found that acute ATRA pretreatment attenuated CDDP-dependent caspase-3
activity in the SK-N-SH cells incubated with the psG5 control vector as seen in Fig. 4.13,
consistent with previous experiments (Fig. 4.2). Analysis of cells incubated with the
dnRARα containing vector suggested that acute ATRA pretreatment mediated
chemoresistance remained unaltered under the conditions of the experiment. This is
indicated by the insignificant difference in caspase-3 activity between SK-N-SH cells
incubated with either the psG5 or the dnRARα containing vector and treated with both
ATRA and CDDP suggesting that the RARα isoform of the retinoid receptor does not
contribute to the observed chemoresistance.

Figure 4.13 RARα does not contribute to acute ATRA pretreatment mediated
chemoresistance
Fluorimetric caspase-3 activity in SK-N-SH cells transfected with either control psG5 or
dnRARα construct containing vector and treated as indicated. Transfection with
dnRARα was unable to alter ATRA-induced chemoresistance under the conditions of
the experiment. The data was normalized to protein content and is expressed as mean
± S.E.M of 4 independent experiments (* p<0.01 vs. control; § p<0.01 vs. CDDP).
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ROLE OF AKT IN ATRA-INDUCED CHEMORESISTANCE

4.14 ATRA increases pAKT (Ser 473) in SK-N-SH neuroblastoma cells
An increased activation of the serine/threonine protein kinase AKT has been
reported in neuroblastoma (Opel et al., 2007). The phosphatidyl inositol-3 kinase (PI3K)
activated AKT protein regulates a range of cellular processes including metabolism,
proliferation, differentiation and apoptosis (Brazil et al., 2002; Nicholson and Anderson,
2002). Moreover, ATRA rapidly activates the PI3K/AKT pathway in the SH-SY-5Y
neuroblastoma cells (Lopez-Carballo et al., 2002). In the continued quest for the
mechanism of the 24 h ATRA exposure dependent chemoresistance, we conducted
preliminary studies to investigate the alteration in the AKT proteins in the SK-N-SH cells
in response to the retinoid.
We observed a significant increase in the levels of active pAKT on exposure to
ATRA at the 30 min, 1 h, 4 h, 24 and 48 h time points as observed in Figs. 4.14A and B.
The results illustrated in Fig. 4.14 indicate that an increase in the phosphorylation of the
protein AKT may contribute to the 24 h ATRA pretreatment induced resistance to CDDP
in the SK-N-SH neuroblatoma cell line. Studies using the PI3K-specific inhibitor
LY294002 have demonstrated activation of the AKT signaling pathway is a requisite for
ATRA dependent differentiation in neuroblastoma cells (Lopez-Carballo et al., 2002). In
view of this finding, future studies using LY294002 will be directed towards confirming
whether the AKT pathway contributes to the observed acute ATRA-dependent
chemoresistance in the SK-N-SH cells.
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A

Figure 4.14 ATRA increases pAKT (Ser 473) in SK-N-SH neuroblastoma cells
(A) Incubation of SK-N-SH cells with ATRA increases pAKT (Ser 473) levels. Western
blot analysis of pAKT expression in cytosolic extracts of SK-N-SH cells (75 µg protein)
demonstrated that ATRA increases pAKT expression at 30 min and 1 h time points.
GAPDH was used as the loading control. Densitometric analysis of 4 independent
experiments is expressed as mean ± S.E.M. (* p<0.05 vs. control).
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B

Figure 4.14(B) Incubation of SK-N-SH cells with ATRA increases pAKT (Ser 473)
levels. Western blot analysis of pAKT expression in cytosolic extracts of SK-N-SH cells
(75 µg protein) demonstrated that ATRA increases pAKT expression at 4 h, 24 h and 48
h time points. GAPDH was used as the loading control. Densitometric analysis of 4
independent experiments is expressed as mean ± S.E.M. (*p<0.05 vs. control).
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STUDY OF CISPLATIN-INDUCED MnSOD EXPRESSION

4.15 CDDP enhances MnSOD while decreasing Cu/ZnSOD expression in SK-N-SH
neuroblastoma cells
An increase in MnSOD expression and activity is reported to constitute an
adaptive response to oxidative stress (Crapo et al., 1974; Wan et al., 1993). Since
MnSOD is upregulated in response to ROS, we examined cytosolic extracts of SK-N-SH
cells exposed to CDDP (0-25 μM) for 24 h by western analysis to determine whether the
chemotherapeutic agent altered expression of the antioxidant enzyme. We found that
MnSOD expression was significantly amplified in cells exposed to the different
concentrations of CDDP (Fig. 4.15A) for 24 h. We also noted that the increase in
MnSOD expression was independent of CDDP concentration in the range of 5 and 25
μM, as there was no significant difference in the levels of the endogenous antioxidant
between treatments.
In order to determine whether the phenomenon of CDDP dependent increase in
expression was specific to the Mn-containing mitochondrial isoform we analyzed the
expression of copper-zinc superoxide dismutase (Cu/ZnSOD). In Fig. 4.15B we
demonstrate that exposure to 5 μM CDDP had no effect on Cu/ZnSOD concentration.
Both 10 and 25 μM concentrations of CDDP were able to significantly (p<0.05)
decrease expression of Cu/ZnSOD when compared to the control cells. The differential
regulation of the SOD proteins has been reported recently in renal tubular cells
(Mishima et al., 2006). This may possibly be a result of the direct effect of CDDP on
mitochondria, which determines sensitivity to the chemotherapeutic agent as
demonstrated by Qian et al., 2005, causing an increase in MnSOD.
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A

B

Figure 4.15 CDDP enhances MnSOD while decreasing Cu/ZnSOD expression in SK-N-SH
neuroblastoma cells
(A) Western blot analysis of MnSOD of SK-N-SH cells exposed to various CDDP concentrations
(0-25 µM). A significant increase in MnSOD expression was observed with 24 h of CDDP
treatment in 75 µg of whole cell lysates. (B) Western blot analysis of Cu/ZnSOD in whole cell
lysates (75 µg) of SK-N-SH cells treated with CDDP (0-25 µM). A significant decrease in
Cu/ZnSOD expression was observed with 24 h of CDDP (10, 25 µM) exposure. GAPDH was
used as the loading control. Results are expressed as mean ± S.E.M. and are representative of
five independent experiments (*p<0.05 vs. control).

65

4.16 MnSOD activity increases in SK-N-SH cells exposed to CDDP for 24 h
After establishing that CDDP stimulated MnSOD expression in SK-N-SH cells,
we evaluated whether this increase in protein translated into active enzyme. The results
from the activity assay demonstrated that a 24 h exposure to CDDP increases MnSOD
activity by approximately 50% (Fig. 4.16) as compared to the control cells,
corresponding to the observed increase in protein. In this experiment, consistent with
protein expression, we showed that the enhanced MnSOD activity was independent of
CDDP concentration in the range of 5 and 25 μM.

In addition, we noted that the

increase in activity was specific for MnSOD suggesting that the mitochondrial isoform of
the antioxidant plays an important role in CDDP-induced alterations in the SK-N-SH
cells. Taken together the SOD protein and activity data indicate that the mitochondria
are specific targets of CDDP therapy in neuroblastoma which is similar to a recent
report of the chemotherapeutic agent in head and neck cancer (Cullen et al., 2007).

Figure 4.16 MnSOD activity increases in SK-N-SH cells exposed to CDDP for 24 h
MnSOD activity increased in SK-N-SH cells exposed to a range of CDDP
concentrations (0-25 µM) for 24 h. Results are expressed as mean ± S.E.M. for four
independent experiments (*p<0.05 vs. control).
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4.17 CDDP increases MnSOD mRNA in the SK-N-SH cell line
Following the observation that CDDP specifically increases MnSOD protein and
activity, we to focused further studies on the regulation of the manganese containing
isoform by the chemotherapeutic agent. Our next experiment investigated whether
CDDP could alter expression of SOD2 mRNA. We isolated mRNA from SK-N-SH cells
treated with CDDP (0-25 μM) for 24 h and subjected the samples to real time RT-PCR
analysis. As can be observed in Fig. 4.17, CDDP concentration independently
increased the relative levels of MnSOD mRNA by approximately 50% in the SK-N-SH
neuroblastoma cells in comparison to untreated control cells, corresponding to the
enhanced expression and activity of the endogenous antioxidant.

Figure 4.17 CDDP increases MnSOD mRNA in the SK-N-SH cell line
Real time RT-PCR studies demonstrate a significant increase in MnSOD mRNA in SKN-SH cells treated with CDDP (0-25 µM). The results are expressed as mean ± S.E.M.
for 3 independent experiments (*p<0.05 vs. control).
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4.18 CDDP does not alter NFκB dependent luciferase activity at 12 and 24 h
It was previously demonstrated that activation of an NFκB enhancer element in
the second intron of the SOD2 gene is essential for the induction of MnSOD by
cytokines including TNFα and IL-1β (Kiningham et al., 2001). In addition, TNFα induces
MnSOD through ROS-mediated activation of NFκB (Menon et al., 1993). Recent studies
in a human colon carcinoma cell line verified that acute apoptosis by CDDP requires
induction of ROS (Berndtsson et al., 2006). Therefore, in order to investigate whether
NFκB contributes to CDDP-induced MnSOD expression, we transfected SK-N-SH cells
with either an empty or test (NFκB reporter) vector to analyze transcriptional alteration
in response to the chemotherapeutic. Following the transfection, we exposed the cells
to CDDP (0-25 μM) for either 12 or 24 h.
Lysates of the treated SK-N-SH cells were subjected to the luciferase activity
assay. Exposure to CDDP (5-25 μM) did not enhance NFκB-dependent luciferase
activity (Fig. 4.18A). On the contrary, as can be seen in Figs. 4.18A and B, CDDP
treatment significantly decreased luciferase activity versus the controls in cells
transfected with either the empty or test vector. The cytokine TNFα (200 IU/ml) was
used as a positive control and produced a significant increase in luciferase activity in
cells transfected with the NFκB reporter construct at both 12 and 24 h versus those
incubated with the empty vector. Taken together, the data in Fig. 4.18 suggests that
NFκB does not contribute to CDDP-dependent MnSOD expression in the concentration
range of 5-25 μM in SK-N-SH cells.
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A

Figure 4.18 CDDP does not alter NFκB dependent luciferase activity at 12 & 24 h
(A) The effect of 24 h CDDP exposure on the expression of NFκB-dependent luciferase
reporter activity. A treatment with CDDP did not alter luciferase reporter activity in cells
transfected with the vector containing the NFκB construct as compared to the respective
control cells. The results are reported as the mean ± S.E.M. (*p<0.05 vs. control-empty
vector; § p<0.05 vs. control-NFκB reporter).
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B

Figure 4.18(B) The effect of 12 h CDDP exposure on NFκB-dependent luciferase
reporter gene. A treatment with CDDP did not alter luciferase reporter activity in cells
transfected with the vector containing the NFκB construct as compared to the respective
control cells. The results are reported as the mean ± S.E.M. (*p<0.05 vs. control-empty
vector; § p<0.05 vs. control-NFκB reporter).
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4.19 MnSOD mediates CDDP-dependent increase in caspase-3 activity and
cleavage
An in-vitro study in human gastric carcinoma demonstrated that MnSOD
produced chemoresistance to doxycycline and mitomycin c (Hur et al., 2003).
Furthermore, a clinical study in breast cancer implicated MnSOD to attenuate the
antitumor effects of adriamycin and cyclophosphamide, both of which are known to
function through generation of ROS (Martin et al., 2006). In contrast to the preceeding
conclusions, MnSOD may mediate apoptosis caused by oxidized LDL and p53
(Kinscherf et al., 1998, Hussain et al., 2004). In view of these paradoxical reports, we
further investigated the function of increased MnSOD protein and activity in the
response to CDDP. We employed SOD2 siRNA to decrease MnSOD in the SK-N-SH
cells and analyzed the samples for caspase-3 activation. This allowed us to determine if
MnSOD protects against CDDP-dependent toxicity.
To verify our ability to decrease MnSOD expression, we performed western
analysis (Fig. 4.19A) of SK-N-SH cells transfected with either control or SOD2 siRNA
(100 nM) for 24 h. Densitometric analysis of 4 independent experiments (Fig. 4.19A)
demonstrates that SOD2 siRNA produced a significant decrease in basal MnSOD
expression (by 75%), as well as that enhanced by CDDP treatment of the SK-N-SH
cells (by 80%) as compared to cells receiving control siRNA. Results from the activity
analysis suggest that corresponding to the decrease in protein expression, there was a
significant reduction in MnSOD activity in vehicle and CDDP treated cells transfected
with SOD2 siRNA (Fig. 4.19B) as compared to cells incubated with control siRNA.
The fluorimetric ApoAlert assay revealed that transfecting SK-N-SH cells with
SOD2 siRNA for 24 h significantly but partially attenuated CDDP-dependent caspase-3
activity (p<0.05; Fig. 4.19C). Therefore, in order to validate the activity results, we
analyzed the samples for caspase-3 cleavage by western analysis. Figure 4.19D
illustrates that corresponding to an increase in activity, the 17 and 19 kDa cleavage
products of caspase-3 appeared in cytosolic extracts of cells exposed to CDDP (Lower
panel; lanes 2 and 4). Furthermore, there was a striking reduction in caspase-3
cleavage in CDDP treated cells transfected with SOD2 siRNA as compared to those
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incubated with control siRNA which is consistent with the activity data of the
proapoptotic protein (Fig. 4.19D; lower panel, lanes 2 and 4). Taken together these
results suggest that the enzyme MnSOD mediates in part, caspase-3 activation induced
by CDDP.

A

Figure 4.19 MnSOD mediates CDDP-dependent increase in caspase-3 activity and
cleavage
(A) Densitometric analysis from 4 independent western experiments for the expression
of MnSOD in SK-N-SH cells transfected with siRNA and treated with CDDP (10 µM) as
indicated. Transfection of cells with SOD2 siRNA significantly decreased basal and
CDDP-induced MnSOD expression. The results are reported as the mean ± S.E.M.
(*p<0.01 vs. control, § p<0.001 vs. CDDP).
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B

C

Figure 4.19(B) MnSOD activity analysis in lysates from SK-N-SH cells transfected with
siRNA (Control or SOD2) and treated with CDDP (10 µM) as indicated. Transfection of
cells with SOD2 siRNA significantly decreased basal and CDDP-dependent MnSOD
activity. The results are reported as the mean ± S.E.M. from 3 independent experiments
(* p<0.01 vs. control, § p<0.001 vs. CDDP). (C) Caspase-3 activity was assessed in SKN-SH cells transfected with siRNA (Control or SOD2) and exposed to CDDP (10 µM)
with the appropriate controls. There was a significant reduction in caspase-3 activity in
CDDP treated cells transfected with SOD2 siRNA as compared to those incubated with
control siRNA. The results are expressed as the mean ± S.E.M. for six independent
experiments (*p<0.001 vs. control, § p<0.05 vs. CDDP).
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D

Figure 4.19(D) Western blot analysis for MnSOD and cleaved caspase-3 in cells
transfected with siRNA (Control or SOD2) and incubated in CDDP (10 µM) with the
necessary controls. Transfection of cells with SOD2 siRNA caused a decrease in both
basal and CDDP-dependent MnSOD expression. In the lower panel it can be seen that
SOD2 siRNA attenuated CDDP-induced appearance of caspase-3 cleavage products
when compared to cells transfected with control siRNA.

4.20 NAC attenuates CDDP-induced caspase-3 activity
We hypothesized that generation of ROS by increased MnSOD activity, mediated
CDDP-dependent alterations in the SK-N-SH neuroblastoma cells (Wang et al., 2008).
Low doses of the antioxidant NAC protected against lipopolysaccharide induced toxicity
by scavenging hydrogen peroxide in rats (Sprong et al., 1998). In addition NAC
successfully attenuated anticancer drug-induced apoptosis in-vitro by quenching
hydrogen peroxide in human small cell lung carcinoma and leukemia (Simizu et al.,
1998). To test our hypothesis, we incubated SK-N-SH cells for 24 h with NAC (1mM)
followed by CDDP (10 µM) coapplication with the antioxidant. Cell lysates were
extracted 24 h following CDDP (10 µM) treatment and analyzed for caspase-3 activity.
Figure 4.20 demonstrates that exposure to CDDP (10 µM) significantly increased
caspase-3 activity, whereas NAC (1mM) had no effect in the SK-N-SH cells. A 24 h
pretreatment with NAC (1mM) significantly attenuated CDDP (10 μM) dependent
caspase-3 activity. This result suggests the contribution of ROS to CDDP-induced
caspase-3 activity in the SK-N-SH cells. Taken together, the results from Figs. 4.19 and
4.20 imply that ROS mediates the contribution of MnSOD to CDDP-induced caspase-3
activity.
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Figure 4.20 NAC attenuates CDDP-induced caspase-3 activity
Caspase-3 activity determined using the ApoAlert fluorescence assay in SK-N-SH cells
24 h after exposure to treatments as indicated. A pretreatment with NAC attenuates
CDDP-induced caspase-3 activity in SK-N-SH cells. The data was normalized to protein
content (Biorad assay) and is expressed as mean ± S.E.M. of 3 independent
experiments (*p<0.001 vs. control; § p<0.05 vs. CDDP).
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STUDY OF ATRA-DEPENDENT MnSOD EXPRESSION AND CHEMORESISTANCE
IN THE SH-SY-5Y CELL LINE

4.21 ATRA exposure increases MnSOD expression in the SH-SY-5Y cell line
In a recent report (Kiningham et al., 2008), we demonstrated that ATRA
significantly increases MnSOD expression in the SK-N-SH cell line starting at 72 h
through the NFκB pathway. As an extension of this study, we plated SH-SY-5Y cells
and exposed them to ATRA (10 µM) for 96 h. We then analyzed the samples for the
expression of MnSOD using western analysis. As can be observed in Fig. 4.21, we
showed that although ATRA had no effect on MnSOD expression at 24 and 48 h, the
retinoid significantly increased the expression of the antioxidant starting at 72 h which
continued until 96 h as compared to the vehicle treated cells. This experiment
substantiates the observation that ATRA exposure increases the expression of MnSOD
in neuroblastoma suggesting the enzyme may contribute to retinoid-induced alteration
in cellular function.
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Figure 4.21 ATRA exposure increases MnSOD expression in the SH-SY-5Y cells
Western blot analysis of MnSOD expression in SH-SY-5Y cells exposed to ATRA for up
to 96 h (75 µg of protein). Exposure to ATRA resulted in a significant increase in
MnSOD expression in the SH-SY-5Y cells starting at 72 h. GAPDH was used as the
loading control. The results are expressed as mean ± S.E.M of 3 independent
experiments (*p<0.05 vs. control). GAPDH was used as a loading control.
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4.22 Acute prior ATRA treatment attenuates prolonged (96 h) CDDP exposure
dependent caspase-3 activity in SH-SY-5Y cells
Building on the study of ATRA-induced chemoresistance, we determined whether
we would observe a similar phenomenon in the SH-SY-5Y cells, a pure culture of
human neuroblasts. We exposed the SH-SY-5Y cells to ATRA, CDDP (0.5 or 1 µM) or
both for 96 h following the 24 h of prior retinoid expoure. Consistent with the previous
study (Fig. 4.4), we observed that an acute pretreament with ATRA significantly
attenuated CDDP (0.5 or 1.0 μM) dependent caspase-3 activity at all time points tested
(Fig. 4.22A-D). The data from 24, 48, 72 and 96 h confirmed the retinoid-induced
chemoresistance phenomenon observed previously in the SK-N-SH neuroblastoma
cells. However in contrast to the SK-N-SH line the SH-SY-5Y exhibited an increasing
sensitivity to CDDP indicated by the higher caspase-3 activity at 96h time point as
compared to 24 h (Fig. 4.22D vs. A).
A

B

Figure 4.22 Acute prior ATRA treatment attenuates prolonged (96 h) CDDP
exposure dependent caspase-3 activity in SH-SY-5Y cells
(A) ATRA mediated chemoresistance in the SH-SY-5Y cell line with CDDP exposure
(48 h) following incubation with the retinoid. Consistent with the observation in the SKN-SH line, acute ATRA pretreatment attenuated CDDP-induced caspase-3 activity in
SH-SY-5Y cells at 24 h (*p<0.05 vs. control; § p<0.05 vs. CDDP) and (B) 48 h (*p<0.05
vs. control; § p<0.05 vs. CDDP). The data was normalized to protein content (Biorad
assay) and is expressed as mean ± S.E.M. of 3 independent experiments.

78

C

D

Figure 4.22(C) ATRA mediated chemoresistance in the SH-SY-5Y cell line with CDDP
exposure (96 h) following incubation with the retinoid. Consistent with the observation in
the SK-N-SH line, acute ATRA pretreatment attenuated CDDP-induced caspase-3
activity in SH-SY-5Y cells at 72 h (*p<0.05 vs. control; § p<0.05 vs. CDDP) and (D) 96 h
(*p<0.05 vs. control; § p<0.05 vs. CDDP). The data was normalized to protein content
(Biorad assay) and is expressed as mean ± S.E.M. of 3 independent experiments.
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CHAPTER V – DISCUSSION
STUDY OF ATRA-INDUCED CHEMORESISTANCE
In the present study, the human SK-N-SH cell line was used as a model of
neuroblastoma, a common childhood cancer. The retinoid responsive SK-N-SH cells
comprise a heterogenous population that can be differentiated into a neuroectodermal
phenotype using agents that promote coordinated morphological, biochemical and
ultrastructural changes (Abemayor and Sidell, 1989). The sympathoadrenal neuroblasts
(N), the substrate-adherent non-neuronal (S), and the intermediate (I) cells constitute
the SK-N-SH line (Ross et al., 2003). The N-type are small rounded cells with short
neuritic processes, whereas the S-type are large, flat, substrate adherent cells. The Itype have a morphology intermediate between that of N and S, are moderately adherent
to the substrate and show small cell body with or without neuritic elongations (Walton et
al., 2004). The I-type is reported to be the most malignant followed by the N-type while
the S-type has little ability to induce tumors (Ross et al., 2003).
The effect of ATRA (10 µM) exposure in the SK-N-SH cells is limited to
differentiation and a reduction in proliferation versus retinoids including 9-cis retinoic
acid that cause apoptosis (Lovat et al., 1997). Modulation of components of the
apoptotic pathway during ATRA-induced differentiation has been correlated to
observation of resistance to cytotoxic agents like CDDP in-vitro (Lombet et al., 2001;
Lasorella et al., 1995). The observed chemoresistance has limited comprehensive use
of retinoids in neuroblastoma therapy. The present study investigated the mechanism
by which ATRA induces chemoresistance. Before analyzing resistance, we conducted
an initial experiment to determine the effect of CDDP on the viability of SK-N-SH human
neuroblastoma cells using the MTT assay. We demonstrated that SK-N-SH cells have a
sensitivity similar to in-vitro models of several tumors including cervical carcinoma,
promyelocytic leukema and normal tissue (Fig. 4.1), as 24 h of CDDP (25 µM)
decreased survival by 40% (Qian et al., 2005).
The chemotherapeutic agent CDDP is effective in treating several solid tumors
including neuroblastoma through the generation of platinum DNA adducts and ROS that
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result in apoptosis (Reedijk et al., 1985, Schaaf et al., 2002). The mechanism by which
the resultant changes induce apoptosis in response to CDDP is not completely
understood. Studies by Seki et al., 2000 and Del Bello et al., 2004 indicated that CDDP
activates both the death receptor and the mitochondrial caspase-9 pathways, which in
turn activate downstream caspases-3 and -7. Caspase-3 in turn cleaves the DNA repair
molecules poly ADP-ribose polymerase (PARP) and DNA endonuclease. At the
mitochondrial level CDDP causes proapoptotic bax and bak to induce cell death through
cytochrome c release (Korsmeyer, 1995; Adams and Cory, 1998). The bcl-2 and bcl-xL
proteins suppress bax dependent effector caspase activation and subsequent apoptosis
at the mitochondria (Zha et al., 1996). The bcl-2 family of proteins thus control neuronal
survival through modulation of apoptosis and have been explored for their involvement
in ATRA-induced chemoresistance in the SK-N-SH neuroblastoma cell line (Davies,
1995; Lombet et al., 2001). In the present study, we demonstrate for the first time that
an acute 24 h ATRA pretreatment significantly attenuated CDDP-dependent increase in
caspase-3 acitivity and cleavage in SK-N-SH cells (Figs. 4.2A and B). Using western
analysis we suggested that chemical interaction plays a minor role in ATRA-dependent
alteration in CDDP function in SK-N-SH human neuroblastoma cells (Fig. 4.3).
Early studies investigating the ATRA-induced resistance have analyzed response
to chemotherapy 4-7 days after exposure to the retinoid with the presumption that
enhanced expression of bcl-2 associated with differentiation led to reduced
responsiveness to cytotoxic agents (Lasorella et al., 1995; Tieu et al., 1999).
Unpublished observations in our laboratory have shown that although the SK-N-SH
cells begin to exhibit biochemical alterations as early as 24 h after ATRA (10 μM)
treatment, complete differentiation as morphologically observed by striking neurite
outgrowth occurs approximately 14 days after retinoid treatment (Reynolds and
Lemons, 2001). However exposure of NB4 neuroblastoma cells to ATRA alters gene
expression within 6 h (Tamayo et al., 1999). The findings of the present report
suggesting early alteration in the expression of genes involved in chemoresistance are
supported by the Tamayo et al. report (1999).
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In the clinical setting, CDDP is administered intravenously in cycles for 1-5 days
at lower doses in combination with other chemotherapeutic agents to treat
neuroblastoma (Berthold and Hero, 2000). Therefore, in order to better represent
clinically used dosing regimens, we designed experiments utilizing lower concentrations
of CDDP (0.5 or 1 μM). We incubated SK-N-SH cells with CDDP (0.5 or 1 μM) for 24
through 96 h in the presence or absence of ATRA following 24 h of pretreatment with
the retinoid. We observed that acute ATRA pretreatment significantly attenuated CDDPdependent caspase-3 activity at 24, 48, 72 and 96 h time points (Figs. 4.4A-D). An
approximately 60% reduction in caspase-3 activity was observed with 96 h of exposure
to 1 μM CDDP vs. a 24 h treatment suggesting the development of drug resistance (Fig.
4.4D vs. Fig. 4.4A). The observation of reduced caspase-3 activity in response to
prolonged exposure to CDDP in the SK-N-SH cells is not surprising. A variety of
mechanisms may contribute to the decreased responsiveness to cytotoxic insult,
including alteration of signaling pathways, modulation of redox status and increased
expulsion of CDDP (Reviewed by Kelland, 1993).

ROLE OF NFκB IN ATRA-INDUCED CHEMORESISTANCE
Experiments conducted by Mantymaa et al. (2000) in acute myeloblastic
leukemia cells have demonstrated that ATRA generates peroxides without altering the
levels of glutathione. In addition, Chen et al., (1991) revealed that ATRA generates
superoxide, which is coupled with differentiation. The ROS generated modulate several
signal transduction pathways as well as alter expression of genes through transcription
factors like NFκB that are sensitive to redox status (Staal et al., 1994; Siebenlist et al.,
1994; Allen and Tresini, 2000). The dimer NFκB is known to maintain normal processes
including communication between cells, progression through the cell cycle and
apoptosis by regulating the expression of genes including cytokines, chemokines,
adhesion molecules and enzymes (Karin, 2006). The review by Karin further highlights
the role of aberrant activation of NFκB in tumorigenesis, evasion of apoptosis and
promotion of cell proliferation, metastasis and angiogenesis leading to survival.
Upregulation of the antiapoptotic bcl-2 and bcl-xL along with downregulation of the
proapototic bax proteins constitute some of the mechanisms by which NFκB regulates
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cell survival (Catz and Johnson, 2001; Huerta-Yepez et al., 2004; Grimm et al., 2005).
An investigation of the ATRA-dependent early changes in the apoptotic pathway
mediated through the generation of ROS and resulting NFκB activation is essential for a
complete

mechanistic

elucidation

of

the

retinoid-induced

chemoresistance

in

neuroblastoma.
The levels of the antipoptotic bcl-2 and bcl-xL proteins are modulated in SK-N-SH
neuroblastoma cells by differentiating agents like ATRA (Reed et al., 1991; Dole et al.,
1991; Lasorella et al., 1995). We observed that ATRA treatment enhanced the
expression of bcl-xL while reducing levels of bcl-2 in SK-N-SH cells (Figs. 4.5 and 4.6).
This is consistent with the report of Lombet et al. (2001) wherein 7 days of ATRA (3 μM)
pretreatment decreased thapsigargin (10 nM) induced cell death by enhancing
expression of bcl-xL. We show for the first time that CDDP treatment reduced the
expression of bcl-xL in SK-N-SH cells. Prior exposure to ATRA attenuated the CDDPinduced decrease in bcl-xL suggesting that the anti-apoptotic protein contributes to the
retinoid-dependent chemoresistance (Fig. 4.5). The role of bcl-xL in the observed
chemoresistance is supported by recent studies in lung carcinoma cells and xenograft
models, which demonstrated inhibitors of antiapoptotic protein to potentiate cytotoxic
drugs both in-vitro and in-vivo (Shoemaker et al., 2006).
Pretreatment with ATRA further decreased CDDP-dependent bcl-2 expression in
the SK-N-SH cells (Fig. 4.6). As ATRA did not enhance bcl-2 expression in the CDDP
treated cells we conclude that the antiapoptotic protein has no role in the observed
chemoresistance. A report indicating that bcl-2 is not critical for resistance to the
chemotherapeutic agent etoposide and γ-irradiation, in the SH-SY-5Y cellular model of
neuroblastoma (Ronca et al., 1999) supports the preceding conclusion. Furthermore, in
the present report using western analysis, we demonstrated that the ATRA pretreatment
attenuated CDDP-dependent bax expression in the SK-N-SH cells (Fig. 4.7). The
reduction in bax expression in ATRA and CDDP treated cells may contribute to the
retinoid-induced chemoresistance. With the preceding results, we demonstrate for the
first time that a 24 h ATRA pretreatment modulates components of the intrinsic
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apoptotic process (bcl-xL and bax in particular), in the SK-N-SH cells, which may
contribute in part to the retinoid-induced resistance to CDDP.
The endogenous antioxidant MnSOD is induced by elevated ROS, and is a target
gene of NFκB (Warner et al., 1996). Overexpression of MnSOD demonstrated that the
mitochondrial antioxidant protects against CDDP-induced apoptosis in murine
fibrosarcoma and human embryonic kidney 293 cells, and even contributed to
differentiation (Zhao et al., 2001; Davis et al., 2001). In addition, MnSOD antisense
sensitized a squamous cell carcinoma line to CDDP (Ueta et al., 2001). In Fig. 4.8 we
demonstrated that exposure of SK-N-SH cells to ATRA increased MnSOD levels.
Moreover, we established for the first time that CDDP increased the expression of
MnSOD in the SK-N-SH human neuroblastoma cell line (Fig. 4.8). Pretreatment with
ATRA further enhanced the expression of MnSOD, implying that the antioxidant
contributes in part to the retinoid-induced chemoresistance. Ahlmeyer et al., (2001)
correlated an upregulation of both Cu/ZnSOD and MnSOD proteins to the ATRAinduced resistance to apoptosis produced by staurosporine in primary rat hippocampal
cultures. Furthermore, induction of MnSOD reduced etoposide-induced apoptosis
(Mantymaa et al., 2000) in acute myeloblastic leukemia cells suggesting a possible role
of the antioxidant in chemoresistance.
We used the SN50 inhibitor peptide to test involvement of NFκB in acute ATRA
pretreatment-induced chemoresistance. Before investigating effects of NFκB blockade,
on ATRA-dependent chemoresistance we analyzed the expression of proteins (MnSOD
and NMDAR1) induced by the retinoid and regulated by the prosurvival transcription
factor (Mantymaa et al., 2000; Sompol et al., 2006; Begni et al., 2003). In Fig. 4.9A, we
demonstrated that SN50 prevented upregulation of MnSOD in SK-N-SH cells exposed
to ATRA, confirming NFκB-dependent alteration of the antioxidant by the retinoid.
Togerson et al. have reported that SN50 (210 μg/ml) inhibited transcription factors other
than NFκB such as AP-1 (1998). In our experimental system, 10 μM ATRA does not
alter transcriptional activity of AP-1 as determined by luciferase-dependent reporter
assays (data not shown). In addition, the concentration of SN50 (5 μg/ml) that was used
in these experiments selectively inhibits NFκB translocation to the nucleus (Kolenko et
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al., 1999). Some investigators explained the possible mechanisms of ATRA-dependent
increase in NFκB activity. Chang et al., 2000, showed that RARα enhances NFκB
mediated reporter activity in the presence of ATRA using deletion and site directed
mutation analyses of a retinoid responsive segment of the human IL-8 gene. In another
report conducted by Manna and Aggarwal, 2000, in human lung cancer cell lines ATRA
upregulated TNF receptors potentiating NFκB activation.
Following MnSOD analysis we showed that ATRA increased NMDAR1 within 48
h of retinoid administration, consistent with the time frame of activation of the NFκB
pathway in the SK-N-SH cells (Kiningham et al., 2008). In addition we verified that
inhibition of NFκB by SN50 can attenuate the ATRA-dependent increase in NMDAR1, a
well-known marker of neuronal differentiation. Previous reports (Begni et al., 2003; Hiroi
et al., 1998; Lau et al., 2004; Basha et al., 2003) suggest that NMDAR1 is regulated by
NF-κB, AP-1, CREB, and SP-1 elements in the promoter region of the human gene. The
results in Fig. 4.9A and B demonstrated that SN50 attenuated ATRA-induced changes
mediated through NFκB and suggest that MnSOD and NMDAR1 expression in the
ATRA-treated SK-N-SH cells is mediated through the redox sensitive transcription
factor. Based on the preceding conclusions we speculate that ATRA-mediated
chemoresistance and differentiation involve pathways which are sensitive to cellular
redox status.
Preliminary studies investigating chemoresistance using the MTT assay revealed
that exposure of the SK-N-SH cells to ATRA (10 μM) alone significantly decreased
absorbance compared to the controls, even though the retinoid did not alter apoptotic
markers (Caspase-3 cleavage and activity, Fig. 4.2). Experiments by Guo et al., 2006
reveal that the ATRA-dependent reduction in cellular proliferation is responsible for the
observed decrease in absorbance, a phenomenon that could interfere with the
presentation of chemoresistance. In view of this, we conducted the ATP dependent
CellTiter-Glo viability assay in which exposure to ATRA (10 μM) alone produced no
change in the luminescence in SK-N-SH cells, allowing investigation of the retinoid
dependent chemoresistance. The CellTiter-Glo assay was carried out in the presence of
SN50 inhibitor peptide to investigate the involvement of NFκB in ATRA-induced
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chemoresistance by attenuating gene regulation by the transcription factor. Incubation
of the SK-N-SH cells with the SN50 inhibitor peptide attenuated the ATRA-dependent
chemoresistance suggesting a role for NFκB in the process (10 µM and 25 µM; Fig.
4.10). However, there was no difference between samples receiving both ATRA and
CDDP incubated with or without SN50, suggesting that NFκB does not contribute to the
retinoid chemoresitance. This conclusion is substantiated by the observation that SN50
prevented CDDP-dependent decrease in luminescence which possibly plays a role in
the observed attenuation of chemoresistance.

ROLE OF MnSOD IN ATRA-INDUCED CHEMORESISTANCE
The observation that preincubation with ATRA enhanced CDDP-dependent
MnSOD expression (Fig. 4.8) suggested that the NFκB target enzyme (MnSOD) could
contribute to the observed chemoresistance. In subsequent experiments, we
demonstrated that NFκB contributes in part to the reduced responsiveness of the SK-NSH cells to CDDP on prior incubation with ATRA (Fig. 4.10) using the SN50 inhibitor
peptide. Similar to the NFκB transcription factor, MnSOD is paradoxically reported to
both aid programmed cell death and attenuate apoptosis or damage induced by
cytotoxic agents in a variety of in-vivo and in-vitro models of cancer, suggesting a
context specific effect of the antioxidant. Removal of superoxide free radicals that
stimulate cell proliferation in-vitro and tumor growth in-vivo contributes to the tumor
suppressive effect of MnSOD in ovarian cancer (Hu et al., 2005). Another report
suggested MnSOD-dependent hydrogen peroxide generation activates caspase-8
leading to apoptosis in colorectal tumor xenografts (Zhang et al., 2006). In contrast,
Delhalle

et

al.

found

that

NF-κB-dependent

MnSOD

expression

protects

adenocarcinoma cells from TNFα-induced apoptosis implying clearance of cytotoxic
ROS by the enzyme as a possible mechanism (2002). Furthermore, overexpression of
MnSOD reduced mitochondrial-initiated poly (ADP-ribose) polymerase-mediated cell
death in murine fibrosarcoma cells by respiratory chain inhibitors as well as CDDPinduced renal injury (Kiningham et al., 1999; Davis et al., 2001).
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To delineate the involvement of MnSOD in ATRA pretreatment induced
resistance to CDDP, we employed SOD2 siRNA to attenuate expression of the
antioxidant enzyme. Observation of SOD2 siRNA-dependent increase in caspase-3
activity in cells exposed to ATRA and CDDP as compared to the corresponding siRNA
transfected

cells

would

suggest

that

MnSOD

contributes

to

the

observed

chemoresistance. We observed that although SOD2 siRNA significantly decreased
CDDP-dependent caspase-3 cleavage and activity, it did not alter ATRA-induced
chemoresistance (Fig. 4.11). The results in figure 4.11 suggested a role of MnSOD in
CDDP-dependent apoptosis and eliminated possible contribution of the enzyme in
ATRA-induced chemoresistance under the conditions of the experiment.

ROLE OF RARα IN ATRA-INDUCED CHEMORESISTANCE
Most studies of ATRA-induced chemoresistance address the possible alteration
in either state of differentiation or alteration in mediators of the apoptotic pathway as
contributors to the process (Lasorella et al., 1995; Tieu et al., 1999). Vitamin A and its
metabolites, including ATRA, mediate their effects mainly through interaction with
nuclear retinoic acid receptors α, β and γ (Laudet and Gronemeyer, 2002). Through
these receptors, ATRA and its analogues alter the transcription of target genes as early
as 1 h after exposure in human and rodent monocytic cells at physiological
concentrations of 10 nM (Chen and Ross, 2007). Moreover, transgenic mice with a
ligand binding defective dominant negative RARα developed B cell lymphomas at a
higher rate compared to wild type littermates (Kupumbati et al., 2006). In view of the
principle role of retinoic acid receptors in mediating function of retinoids it is highly
probable that they contribute to the observed ATRA-dependent reduction in response to
CDDP.
As the RARα isoform the most potent inducer of ATRA mediated transcription,
we conducted studies using a dominant negative specific for that particular receptor
(Idres et al., 2002). Studies with dnRARα would provide information on the possible
involvement of the RARα in acute ATRA pretreatment induced resistance to CDDP in
the SK-N-SH neuroblastoma cells. In figure 4.12A, we show that the dnRARα containing
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vector significantly attenuated ATRA dependent RARE luciferase reporter activity,
suggesting the potential to attenuate retinoid receptor mediated transcriptional activity.
We verified the ability of dnRARα to attenuate the RARα function by demonstrating that
the vector containing dnRARα attenuated ATRA-dependent expression of the target
gene CRABP2 (Fig. 4.12B; Boylan et al., 1995). In agreement, we observed a reduction
in ATRA-induced MnSOD levels in SK-N-SH cells incubated with dnRARα supporting
the preceding evidence (Fig. 4.12C). In critical experiments, we observed that the
dnRARα did not alter the acute ATRA-dependent chemoresistance, thereby eliminating
a possible contribution of RARα in the process under the conditions of the experiment
(Fig. 4.12). Studies conducted in B-cell chronic lymphocytic leukemia cells by Pepper et
al., 2002, have demonstrated that ATRA induced apoptosis is independent of p53, the
retinoid receptors and differentiation supporting our conclusion. In addition receptor
independent effects of ATRA are demonstrated by a recent report demonstrating that
the retinoid promoted cell survival through activation of orphan PPARβ/δ in a human
keratinocyte cell line (Schug et al., 2007). Other isoforms of the RAR’s or an alteration
in cellular process independent of the classical retinoid receptors, are possible alternate
mediators of the acute ATRA-induced chemoresistance.

ROLE OF AKT IN ATRA-INDUCED CHEMORESISTANCE
Alteration in gene expression occured as early as 1 h after exposure to 10 nM of
ATRA in human and rodent monocytic cells (Chen and Ross, 2007). In neuroblastoma
increased activation of the serine/threonine protein kinase AKT is correlated with a poor
outcome, especially when combined with other risk factors such as MYCN amplification
and unfavorable histology (Opel et al., 2007). As ATRA pretreatment induced
chemoresistance within 24 h, we examined possible alterations in the PI3K survival
pathways which are rapidly stimulated in response to the retinoid in the SH-SY-5Y
neuroblastoma cells (Lopez-Carballo et al., 2002; Masia et al., 2007). Having already
eliminated the contributions of MnSOD and RARα in acute ATRA pretreatmentdependent chemoresistance, we hypothesized that activation of the PI3K/AKT pathway
contributed to the ATRA-dependent chemoresistance in the SK-N-SH cells.
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In the first study investigating this hypothesis, we observed a significant increase
in the levels of active pAKT after 30 min, 1 h, 4 h, 24 and 48 h ATRA exposure in the
SK-N-SH cells (Fig. 4.14). These results imply that an increase in AKT phosphorylation
may contribute to the 24 h ATRA pretreatment induced resistance to CDDP (Fig. 4.14).
The AKT signaling pathway is requisite for ATRA dependent differentiation in SH-SY-5Y
neuroblastoma cells, suggesting that the prosurvival pathway is an integral component
of the celluar alterations induced by the retinoid (Lopez-Carballo et al., 2002). A recent
review elaborated that the activation of the AKT pathway by numerous growth factors
including IGF-1, neurotrophins, VEGF, EGF and PDF mediated survival (Sartelet et al.,
2008). Strikingly BDNF activation of TrkB is reported to protect the SH-SY-5Y
neuroblastoma cells from chemotherapy-induced apoptosis via the PI3K pathway
(Jaboin et al., 2002). Future studies will, therefore, be directed towards assessing
whether the AKT pathway contributes to the observed acute ATRA-dependent
chemoresistance in the SK-N-SH cells. Our conclusions on the mechanisms of acute
ATRA pretreatment induced chemoresistance are summarized in figure 5.1. These
observation that an acute pretreatment with ATRA of 24 h induced chemoresistance to
CDDP is important as it suggests that caution should be taken while developing
therapeutic strategies using ATRA as a therapeutic tool in neuroblastoma.
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Figure 5.1 Proposed mechanism of acute ATRA pretreatment-dependent
resistance to CDDP in the SK-N-SH cells.
The chemotherapeutic agent CDDP induces apoptosis (caspase-3 activation) through
DNA damage and generation of ROS leading to mitochondrial damage in part via an
increase in bax (proapototic). Pretreatment with ATRA (24 h) activates the NFκB and
AKT pathway. The transcription factor NFκB attenuates CDDP-induced cytotoxicity in
part through enhanced expression of bcl-xL and the reduction in levels of bax. Future
studies will be directed towards the role of the AKT pathway in chemoresistance. (Grey
arrows – ATRA pretreatment induced effects; Black arrows – CDDP-induced effects).
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STUDY OF CISPLATIN-INDUCED MnSOD EXPRESSION
Siddik (2003) reviewed our increasing understanding of the mechanisms by
which CDDP induces apoptosis. In-vitro studies in human lung cancer and squamous
cell carcinoma showed that exposure to chemotherapeutics like CDDP increases
generation of ROS including superoxide, hydroxyl radical and hydrogen peroxide in and
around mitochondria (Wang et al., 2008; Li et al., 2004). In accordance with these
studies, Qian et al. (2005) showed that a higher density of mitochondria increases
cellular sensitivity to CDDP, emphasizing the crucial role of this organelle in cytotoxicity
induced by the chemotherapeutic agent.
This is the first report to our knowledge to demonstrate that CDDP upregulates
the enzyme MnSOD in the human SK-N-SH neuroblastoma cell line. We also show a
significant increase in MnSOD activity and mRNA corresponding to the enhanced
protein expression (Figs. 4.16 and 4.17). In agreement with the present report, antineoplastic agents including paclitaxel and vincristine induce MnSOD in the lung
adenocarcinoma cell line A549 (Das et al., 1998). Moreover, the DNA-damaging
compound etoposide (10 µM) increases MnSOD expression by about 2 fold within 12 h
in an acute myeloblastic leukemia cell line (Mantymaa et al., 2000). In this report, we
detected a similar increase in MnSOD protein (Fig. 2 A) by incubating SK-N-SH cells for
24 h with 5-25 µM CDDP. The CDDP-induced alteration in MnSOD was independent of
concentration in the range (5-25 µM) tested. We found that the higher concentrations of
CDDP significantly reduced expression of Cu/ZnSOD isoform. Moreover, we show a
significant (p<0.05) increase in MnSOD activity alone, (Fig. 4.16) demonstrating
specificity of CDDP for the manganese isoform. The differential regulation of the SOD
enzymes by CDDP implicates mitochondrial specific proteins, MnSOD in particular, as
important mediators of CDDP-induced toxicity or a defense mechanism against ROS,
supported by the findings of Qian et al. (2005). Although we observed a reduction in
Cu/ZnSOD, the activity of the antioxidant was unaltered (data not shown) leading us to
focus on the role of the manganese isoform in response to CDDP.
Our next experiment investigated the mechanism of CDDP-induced MnSOD
upregulation. In addition to DNA damage, CDDP has been shown to induce cell death
by modifying signaling pathways involving ROS (Schaaf et al., 2002). Also, altered
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redox determines outcome in response to apoptosis inducing agents, with low levels of
ROS promoting survival and higher amounts leading to death (Slater et al., 1995;
reviewed in Kinnula and Crapo, 2004). The ability of ROS to alter apoptosis is mediated
through modulation of transcription, as elaborately demonstrated by Liu et al. (2005).
This observation led us to investigate whether CDDP activated NFκB, particularly since
we have recently demonstrated MnSOD induction to be dependent on the redox
sensitive transcription factor in the SK-N-SH cell line in response to 10 µM ATRA
(Kiningham et al., 2008). In figures 4.18 A and B, we show that the luciferase activity is
unaltered in SK-N-SH cells transfected with a NFκB reporter and incubated with CDDP
as compared to those receiving empty vector. Extending the CDDP exposure to 24 h
did not enhance NFκB dependent luciferase activity indicating that the transcription
factor does not contribute to the increase in MnSOD protein. The human MnSOD
promoter region contains binding sites for several transcription factors including the
redox sensitive p53 (Hussain et al., 2004), FOXO3a (Kops et al., 2002) and SP-1(Xu et
al., 2002), all of which may be potential contributors to MnSOD induction. Moreover, the
second intron of the human MnSOD gene contains binding sites for transcription factors
including NFκB, C/EBP and NF-1 which may potentially contribute to the increase in
MnSOD expression (Xu et al., 1999). Future studies will be directed towards defining
the mediators of the CDDP-dependent increase in MnSOD, with special emphasis on
p53 which is known to play a role in apoptosis induced by this chemotherapeutic agent
in neuroblastoma (Tweddle et al., 2003).
Several prior studies have focused on elucidating the role of MnSOD in cell
survival and apoptosis. Human melanoma and histiocytic lymphoma cell lines stably
transduced with MnSOD were demonstrated to generate higher number of colonies in
semi-solid medium, in presence of doxorubicin as compared to wild type controls
(Suresh et al., 2003). In a recent report, SOD mimetics were found to extend lifespan
and increase cellular proliferation along with angiogenesis (Quick et al., 2008; Juarez et
al., 2006). Overexpression of MnSOD in human embryonic kidney cells attenuated
CDDP-induced apoptosis and increased clonogenic potential (Davis et al., 2001),
indicating the importance of superoxide anion to promote cytotoxicity. Experiments in
murine fibrosarcoma cells established that MnSOD overexpression could protect from
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5-azacytidine-induced apoptosis and promote differentiation (Zhao et al., 2001).
Furthermore, in acute myeloblastic leukemia cells, preservation of MnSOD is
responsible for protection against retinoid induced-apoptosis (Mantymaa et al., 2000).
In contrast to the prosurvival characteristic of MnSOD, a decrease in activity of
the enzyme was first reported in SV-40 transformed WI-38 (VA-13) cells versus controls
(WI-38), implicating the antioxidant as a tumor suppressor (Yamanaka and Deamer,
1974; Dionisi et al., 1975). The mechanism of loss of MnSOD in various cancer cells is
similar to that suggested for tumor suppressor genes including abnormal methylation
(Huang et al., 1999), loss of heterozygosity (Liang et al., 1994) or a mutation in the
promoter of the gene or coding sequence (Xu et al., 1999; Hernandez and McCord,
2003). Ohse et al., 2001, demonstrated mimetics of SOD to induce cancer selective
damage through the generation of hydrogen peroxide, while McFadden et al., 2003,
reported that the synthetic antioxidants protected cochlear hair cells from gentamicin but
not CDDP toxicity. Another study indicated MnSOD is a p53 responsive gene in LiFraumeni syndrome (LFS) fibroblasts, demonstrating that the enzyme mediates
apoptosis in some model systems (Hussain et al., 2004).
In view of the paradoxical reports on the function of MnSOD, we used SOD2
siRNA to significantly reduce basal and CDDP-induced MnSOD expression. This
permitted us to evaluate the possible function of the CDDP-dependent increase in
MnSOD protein and activity in SK-N-SH cells. We showed for the first time that MnSOD
contributes to CDDP-induced cytotoxicity by decreased caspase-3 activity and cleavage
in response to the chemotherapeutic agent in cells transfected with SOD2 siRNA (Figs.
4.19 C and D). Although the CDDP-induced caspase-3 activity and cleavage data follow
a similar trend in terms of the SOD2 siRNA-dependent decrease, the reduction is more
striking in the western analysis. This finding may be a result of time of collection of the
samples (at 24 h), when caspase-3 activity is on the decline while the protein can
clearly be detected by western analysis. Consistent with our results, exposure to the
topoisomerase II inhibitor etoposide, also known to generate ROS, enhanced MnSOD
expression in acute myeloblastic leukemia cells (Pham and Hedley, 2001; Mantymaa et
al., 2000). In contrast to our study, increased MnSOD conferred resistance to apoptosis
which may be due to specificity for acute myeloblastic leukemia (Hu and Brindle, 2005).
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The data in this report demonstrates a possible tumor suppressor effect of
MnSOD in human neuroblastoma. A probable mechanism, by which MnSOD promotes
apoptosis, therefore antagonizing tumors in response to CDDP, is generation of
hydrogen peroxide following dismutation of superoxide anion. Hydrogen peroxide has
recently been reported to mediate bcl-2 down-regulation by CDDP in human lung
cancer cells (Wang et al., 2008). A previous study demonstrated that the antioxidant
NAC

rescued

human

small

cell

lung

carcinoma

and

fibroblast

lines

from

chemotherapeutics including melphalan, carboplatin and CDDP (Muldoon et al., 2001).
We therefore used the hydrogen peroxide scavenger NAC to test the probable role of
the potent ROS in MnSOD-dependent activation of caspase-3. In Fig. 4.20, we
demonstrate that NAC significantly reduced CDDP-dependent caspase-3 activity in SKN-SH cells. This result in Fig. 4.20 suggests the role of ROS in CDDP-induced
apoptosis in SK-N-SH cells and implicates them as mediators of the tumor suppressor
function of MnSOD. The latter possibility is supported by a report by Rodriguez et al.
conducted in human fibrosarcoma cells, wherein catalase was found to reverse the
MnSOD-dependent inhibition of cell growth (2000). Moreover, the potent tumor
suppressive effect of a highly active, mutant form of MnSOD, both in-vitro and in-vivo,
provided further evidence for the anticancer effects of hydrogen peroxide (Davis et al.,
2004).
Another possible mechanism of the tumor suppressive effect of an increase in
MnSOD is the resulting imbalance between proteins that eliminate the different ROS in
various compartments of the cell, altering signal transduction pathways ultimately
promoting apoptosis (Hussain et al., 2004; Ridnour et al., 2004; reviewed in Oberley,
2005). Finally the increase in MnSOD in response to CDDP may cause a change in the
redox status of the cells, altering the expression of specific genes resulting in the
observed tumor suppressive effect (Kiningham and St. Clair, 1997).
In conclusion, we demonstrate for the first time that CDDP induces MnSOD
expression, activity and mRNA in the SK-N-SH human neuroblastoma cell line. We also
establish MnSOD as a mediator of CDDP-induced cytotoxicity, thereby extending
knowledge of the mechanism of the chemotherapeutic agent in neuroblastoma. It is
possible that an altered redox status from the increase in MnSOD, changes
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transcription permitting the antioxidant to regulate CDDP dependent apoptosis. This
possibility is supported by the finding that NAC attenuates CDDP-induced apoptosis in
the SK-N-SH cells. Studies on the CDDP-dependent increase in MnSOD suggest that
the enzyme can be a target in maximizing the effectiveness of chemotherapeutic agents
(Summarized in figure 5.2).

Figure 5.2 Proposed mechanism of MnSOD contribution to CDDP-dependent
cytotoxicity.
In the present report CDDP-dependent increase in MnSOD in the SK-N-SH cells
enhanced caspase-3 activity in response to the apoptotic agent. Prior incubation with
NAC inhibited CDDP-induced caspase-3 activity which is hypothesized to result from
attenuation of ROS including hydrogen peroxide. (Pointed arrow – activation; Blunt
arrow – inhibition).
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ATRA-DEPENDENT INCREASE IN MnSOD AND RESISTANCE TO CDDP IN THE
SH-SY-5Y CELL LINE
We recently demonstrated a significant increase in MnSOD expression in the SKN-SH cells incubated with ATRA for more than 72 h (Kiningham et al., 2008). Activation
of the classical NFκB pathway was established to mediate the ATRA-dependent
increase in MnSOD expression. The enhanced level of MnSOD was hypothesized to
contribute to ATRA-induced alterations in neuroblastoma. As mentioned previously the
SK-N-SH line is a mixed culture of cells obtained from the bone marrow tumor of a 4 yr
old girl. The SK-N-SH line, therefore, represents most neuroblastoma tumors which are
composed of a mixture of histologically distinct malignant cells identified as the
neuroblastic, intermediate and stromal phenotypes (Roald, 2000). However, the N-type
cells are predominant in the common neuroblastoma tumors, growing in culture as
poorly attached aggregates, possessing enzymes to synthesize neurotransmitters,
being MYCN amplified and tumorigenic in mice (Armstrong et al., 2006). Constitutive
activity of NFκB was required for survival in S-type cells (Bian et al., 2002). On the other
hand, doxorubicin-induced activation of the transcription factor NFκB mediated through
p53 leads to apoptosis in the N-type cells (Bian et al., 2001; Armstrong et al., 2006).
In order to further investigate the recently reported ATRA-induced increased
expression of MnSOD in neuroblastoma, we analyzed the expression of the antioxidant
enzyme in the SH-SY-5Y cell line exposed to the retinoid. The SH-SY-5Y cells
constitute N-type neuroblasts alone, exhibiting multiple, short, fine, cell processes
(neurites) cloned from the SK-N-SH line. In the present study we demonstrated an
increase in the levels of MnSOD in the SH-SY-5Y human neuroblastoma line similar to
that recently reported in the SK-N-SH cells (Fig. 4.21). The observation of ATRAinduced increase in MnSOD in two different neuroblastoma cell lines implies that the
enzyme may be an important contributor of retinoid-induced alteration in cellular
function. Our next step was to determine whether exposure to ATRA would induce
resistance to CDDP in the SH-SY-5Y N-type cells corresponding to that in the SK-N-SH
line. A time course experiment in the SH-SY-5Y cell line, consistent with the previous
study, revealed that acute pretreament with ATRA significantly attenuated CDDP (0.5 or
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1.0 μM) dependent caspase-3 activity at all times tested (Fig. 4.22A-D). This result
verifies the phenomenon of acute retinoid-induced chemoresistance observed in the
SK-N-SH neuroblastoma cells. Examining the data closely we observed that in contrast
to the decreased sensitivity of the SK-N-SH cells to CDDP over time, the SH-SY-5Y
cells were more sensitive. This observation demonstrated that the two neuroblastoma
cell lines used differ intrinsically and highlighted the significance of the phenomena
common to both including the increase in MnSOD and the acute ATRA pretreatment
induced chemoresistance.
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FUTURE STUDIES
The results of the present report provide a basis for additional experiments to
advance the knowledge of ATRA pretreatment induced resistance to CDDP. Initially, it
will be important to substantiate the observation that ATRA induces resistance using an
in-vivo model of neuroblastoma. As chemotherapy commonly involves exposure to
multiple agents in cycles, it will be important to determine whether ATRA can induce
chemoresistance in similar, clinically relevant, experimental conditions in-vivo.
The identity of the mediator of acute ATRA pretreatment induced resistance to
CDDP remains elusive. The next experiment to determine the possible contribution of
the AKT pathway would be to analyze acute ATRA pretreatment dependent
chemoresistance in the presence of the PI3K inhibitor LY294002. Following this study it
will be imperative to conduct experiments to investigate the role of possible mediators
such as retinoid receptors and hydrogen peroxide using the lower concentrations of
CDDP (0.5-1 µM) in ATRA induced chemoresistance. Close analysis of the data in the
present report reveals the CDDP-induced cytotoxicity to be concentration dependent at
lower levels of exposure in the SK-N-SH in-vitro model of neuroblastoma, thereby
providing the ideal experimental conditions for mechanistic studies. These experiments
would provide important information to completely explore involvement of the possible
mediators of ATRA-induced chemoresistance. An upregulation of bcl-xL as well as a
decreased expression of bax in CDDP treated SK-N-SH cells via the NFκB pathway
contributes in part to the ATRA induced resistance to apoptosis. Studies using inhibitors
of bcl-xL would further test the role of the prosurvival protein in ATRA-induced
chemoresistance. The results of bcl-xL inhibitor experiment would also supply a
potential strategy to overcome ATRA-induced chemoresistance. Future studies should
also be conducted to identify upstream mediators of the NFκB pathway which contribute
to chemoresistance, thereby providing pharmacological targets to improve the clinical
use of retinoids.
In order to elucidate the function of the ATRA dependent increase in MnSOD it
will be crucial to conduct experiments to determine whether MnSOD is essential for
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ATRA-mediated differentiation. In addition, it is necessary to ascertain whether ATRAinduced MnSOD upregulation is dependent entirely on activation of the NF-κB pathway
or is contingent on retinoid receptor activity. The results from the preceding experiments
will provide possible therapeutic targets to modulate ATRA-induced differentiation
therapy in neuroblastoma. Further investigation into the components of the CDDPinduced increase in MnSOD could yield targets for development of drugs to enhance
cytotoxic effects of the chemotherapeutic agent. The transcription factors p53 and
FOXO3a should be explored for their involvement in regulation of MnSOD by CDDP.
The observation that MnSOD contributes to CDDP-induced apoptosis needs to be
investigated further using SOD mimetics and polyethylene glycol catalase (PEG-CAT).
The experiments with mimetics and PEG-CAT would advance the results of the present
report providing mechanistic information on the involvement of MnSOD and the specific
ROS hydrogen peroxide in the toxicity of CDDP in the SK-N-SH+ neuroblastoma cells.
Conducting these proposed experiments would provide vital information that could be
used to improve ATRA and CDDP therapy in neuroblastoma.
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